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ABSTRACT OF THE DISSERTATION
Tissue Engineering of Induced Pluripotent Stem Cells for the Development of Novel Treatment
Strategies for Osteoarthritis
by
Alison Ross
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2020
Professor Farshid Guilak, Chair
Osteoarthritis (OA) is a debilitating joint disease that is primarily characterized by the
degeneration of articular cartilage, the soft connective tissue that covers articulating bone
surfaces in diarthrodial joints. While there are a number of risk factors for developing OA, the
progression of this disease is mediated in part by pro-inflammatory cytokines from both the
synovium and chondrocytes, the resident cells of articular cartilage. These cytokines, specifically
interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF-α), induce aberrant expression of
catabolic and degradative enzymes and inflammatory cytokines in OA, which promotes
degradation of engineered tissues as well as native articular cartilage. This loss of the
homeostatic balance in chondrocytes results in a challenging environment for cartilage repair and
regeneration.
In the first aim of this dissertation, we show that the combination of gene therapy and
tissue engineering can be applied for the development of an artificial gene circuit in murine
induced pluripotent stem cells (miPSC). This system is based on a NF-κB responsive synthetic
promoter, which drives expression of a therapeutic transgene (interleukin-1 receptor antagonist,
IL-1Ra) and is packaged into a lentiviral vector (NRE-IL1Ra), and results in inflammationxi

driven, self-regulating delivery of biologic drugs. miPSCs were transduced with NRE-IL1Ra in
monolayer or through biomaterial-mediated transduction and were either maintained in
monolayer or differentiated into cartilage constructs. For both of these delivery methods,
stimulation with various doses of IL-1 resulted in production of high levels of IL-1Ra, which
inhibited inflammatory signaling and protected tissue-engineered cartilage from proteoglycan
degradation.
In the second aim of this dissertation, we determined novel therapeutic targets in the
response of tissue-engineered cartilage to inflammatory cytokines. MicroRNAs (miRNAs) are
important regulatory molecules that have been implicated in many diseases, including OA.
However, the specific roles and regulatory networks of miRNAs in response to IL-1 and TNF-α
have not been elucidated. We performed miRNA and mRNA sequencing to determine the
temporal and dynamic responses of miRNAs and genes to IL-1 and TNF-α. We found genes and
miRNAs that were differentially expressed with both cytokines, and also those that were unique
to IL-1 or TNF-α. Through integration of miRNA and mRNA sequencing data sets, we created
networks of miRNA-mRNA interactions and identified hub miRNAs miR-17-5p, miR-20a-5p,
and miR-29b-3p. Delivery of miR-17-5p and miR-20a-5p mimics in combination decreased
degradative enzyme activity levels and expression of inflammation-related genes in cytokine
treated cells.
The work presented in this dissertation improves our understanding of the mechanisms
driving inflammatory responses in OA and provides novel strategies and therapeutic targets to
prevent inflammation-driven degradation of native and tissue-engineered cartilage.

xii

Chapter 1: Introduction
1.1 Osteoarthritis and articular cartilage
Osteoarthritis (OA) affects over 30 million adults in the United States (Cisternas et al.,
2016) and it is the most common form of arthritis, which is the leading cause of disability in the
United States (Lawrence et al., 2008). The risk factors for developing OA include trauma,
obesity, inflammation, aging, metabolic disorder, and genetics (Abramson & Attur, 2009;
O’Neill et al., 2018). The number of individuals with OA is expected to rise due to a more
elderly population, a higher prevalence of obesity, and an increasing incidence of sports-related
injuries leading to individuals in their 30s and 40s being more likely to develop OA (Gage et al.,
2012; O’Neill et al., 2018; Roos, 2005). OA is a major cause of disability worldwide; individuals
with OA and subsequent activity limitations have a higher risk of all-cause mortality (Palazzo et
al., 2016). Additionally, there is a significant economic burden of OA, including both direct and
indirect healthcare costs primarily due to total joint arthroplasty and productivity losses,
respectively. These losses are estimated to cost between 1-2.5% of gross domestic product in
developed countries (Hiligsmann et al., 2013; March & Bachmeier, 1998). Thus, in addition to
the impact of OA on the quality of life and the health of affected individuals, there is also a
significant economic burden with this disease.
OA is primarily characterized by the degeneration of articular cartilage, the soft
connective tissue that covers articulating bone surfaces in diarthrodial joints. This hyaline
cartilage is a highly hydrated tissue with a dense extracellular matrix (ECM) primarily composed
1

of type II collagen and aggrecan, a large aggregating proteoglycan. Collagens make up the
largest portion of the solid phase of articular cartilage. Type II collagen comprises 90-95% of the
collagen in the ECM, with minor collagens, such as types I, III, IV, V, VI, IX, and XI, helping to
form the type II collagen network, providing essential structure and organization (Luo et al.,
2017). This collagen network contributes to articular cartilage’s mechanical properties,
particularly in shear and tension. Proteoglycans are the second most abundant organic
component in articular cartilage and consist of many negatively charged glycosaminoglycan
(GAG) chains covalently bound to a protein core. The high density of negative charges leads to a
resultant swelling pressure in cartilage, contributing to the compressive properties of articular
cartilage. Additionally, there is a sparse population of resident cells, chondrocytes, which
constitute only 1-2% of the total cartilage volume. Chondrocytes metabolically respond to a
variety of stimuli, including growth factors, mechanical loads, and hydrostatic pressures to
maintain the structure and function of articular cartilage through low-turnover replacement of
ECM proteins, primarily GAGs. Importantly, articular cartilage has a zonal structure in which
the orientation of collagen fibrils, concentration of ECM components, and arrangement, shape,
and size of cells varies with depth from the articulating surface (Mow et al., 1992; Sophia Fox et
al., 2009). Because of this structure, articular cartilage has unique compressive, tensile, and
viscoelastic properties, and is able to bear loads, dissipate energy, and provide joint lubrication.
This allows for a near-frictionless and wear resistant surface for decades of use in healthy or noninjured individuals.
In addition to the degeneration of articular cartilage, subchondral bone thickening,
osteophyte formation, cartilage calcification, and modification of synovial fluid composition are
also characteristics of OA. Additional complications include inflammation of the synovial lining,
2

degeneration of ligaments, and sometimes changes in the periarticular muscles, nerves, bursa,
and local fat pads. Thus, OA is disease of the entire joint in which the synovium, bone, cartilage,
and other joint tissues collectively contribute to pain, inflammation, and stiffness, limiting
mobility in affected individuals (Goldring et al., 2017; Loeser et al., 2012).

1.2 Inflammation and OA
Although OA was historically considered a non-inflammatory arthropathy, the role of
inflammation in disease progression is now well recognized (Goldring & Otero, 2011). This is
evidenced by symptoms such as joint pain, swelling, and stiffness, as well as increased
expression of inflammatory mediators, matrix degrading proteinases, and stress response factors
in the early phase of disease (Favero et al., 2015). Furthermore, activation of inflammatory
pathways contributes to the prolonged homeostatic imbalance of cartilage and subsequent
disease progression regardless of the cause of disease initiation.
Inflammatory signaling pathways are activated in chondrocytes by a variety of stimuli,
including trauma or abnormal mechanical load, altered amounts or organization of matrix
proteins, and biochemical mediators such as inflammatory cytokines, chemokines and adipokines
(Goldring et al., 2017). Chondrocytes are responsive to mechanical loads, and physiologic
loading is important for regulating cartilage ECM, growth, and differentiation and can suppress
the effects of proinflammatory cytokines. However, unloading or hyperphysiologic loads will
induce catabolic activity and proinflammatory responses in chondrocytes (Sanchez-Adams et al.,
2014). Once matrix damage has occurred, chondrocytes will be exposed to ECM molecules or
3

fragments that are normally shielded by the protective pericellular matrix. Chondrocytes have
receptors for these proteins, and binding causes upregulation of matrix-degrading enzymes,
inflammatory cytokines, and chemokines (Goldring & Otero, 2011). The synovium can become
inflamed following joint injury, releasing cytokines, chemokines, and other soluble mediators
into the synovial fluid.
Pro-inflammatory cytokines from both the synovium and chondrocytes induce aberrant
expression of catabolic and inflammation-related genes. Interleukin-1 beta (IL-1β) and tumor
necrosis factor-alpha (TNF-α) are considered the primary pro-inflammatory cytokines in OA
(Kapoor et al., 2011b). These cytokines are elevated in synovial fluid, synovial membrane,
subchondral bone, and cartilage of patients with OA. IL-1β is elevated in the synovial fluid from
0.020 ng/mL in patients without disease to 0.021-0.146 ng/mL individuals with OA (Hopkins et
al., 1988; Kahle et al., 1992) and TNF-α has been measured at 0.105-0.124 ng/mL in patients
with OA (Hussein et al., 2008; Özler et al., 2016). IL-1β and TNF-α act by suppressing synthesis
of cartilage matrix components, such as type II collagen and aggrecan, and by activating
inflammatory signaling pathways, including the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) and mitogen activated protein kinases (MAPK) pathways through
extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinase (JNK) and the p38 kinase
cascade (Berenbaum, 2004; Rigoglou & Papavassiliou, 2013). Signaling through these pathways
induces the expression of catabolic and degradative enzymes and inflammatory cytokines.
Matrix metalloproteinases (MMPs) and a disintegrin-like and metalloproteinase with
thrombospondin type 1 motifs (ADAMTS) family members are the main cartilage ECM
degrading enzymes in OA. MMPs include collagenases (MMP-1 and -13), aggrecanases (MMP13), and other matrix degrading enzymes (MMP-2, -3, and -9). However, MMP-13 is the critical
4

MMP in OA due to its dual targeting and a high activity to type II collagen (El-Sayed et al.,
2019). ADAMTS-4 and ADAMTS-5 are also aggrecanases that drive cartilage degradation in
OA (Bondeson et al., 2008). Additionally, IL-1β and TNF-α will induce expression of
interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoattractant protein-1/C-C motif
chemokine ligand 2 (MCP-1/CCL2), inducible nitric oxide synthase (iNOS), cyclooxygenase2/prostaglandin-endoperoxide synthase 2 (COX-2/PTGS2), prostaglandin E2 (PGE2), and nitric
oxide (NO), which are inflammatory mediators, creating a positive feedback loop that further
amplifies and progresses cartilage degradation.

1.3 Current strategies for the treatment of OA
Articular cartilage is avascular, aneural, and alymphatic, and therefore lacks an intrinsic
ability to repair (Abramson & Attur, 2009). Furthermore, the inflammatory environment within
an OA joint provides a challenging environment for articular cartilage repair. Treatment options
for individuals with OA include non-surgical and surgical options, as well as drug therapies
(Roseti et al., 2019). Non-surgical options include lifestyle changes to reduce weight in obese
individuals, physical rehabilitation, and exercise to maintain muscle strength and flexibility.
Current surgical treatments, including autologous chondrocyte implantation, osteochondral
grafting, microfracture, autografts, and allografts, result in tissue with inferior mechanical and
biochemical properties, failing to provide a long-term solution (McNickle et al., 2008; L. Zhang
et al., 2009). Non-steroidal anti-inflammatory drugs (NSAIDS), analgesic drugs, local
administration of corticosteroids, and viscosupplements are commonly prescribed for OA pain,
5

however these palliative treatments have not been shown to inhibit disease progression (Kapoor
et al., 2011b; Oo et al., 2018). Eventually, total joint replacement will be necessary. While this
procedure is effective in the aging population, it is not sufficient for younger patients as they
often outlive the lifetime of the implants, requiring revision surgery (Polkowski et al., 2012).
Additional drug therapies have been developed to overcome the limitations of nonspecific approaches, including a number of anti-cytokine therapies targeting IL-1 and TNF-α. IL1 receptor antagonist (IL-1Ra) is a natural inhibitor of IL-1 signaling that competes with IL-1 for
IL-1 receptor binding. When IL-1Ra is bound to the IL-1 receptor, downstream signaling
pathways are not activated (Seckinger & Dayer, 1987). Previous studies have shown that local
delivery of recombinant human IL-1Ra reduced knee pain and improved joint function following
joint injury (Furman et al., 2014b; Kraus, Birmingham, Stabler, Feng, Taylor, Moorman, et al.,
2012). TNF-α targeting therapies include monoclonal antibodies (infliximab, adalimumab,
golimumab) and the soluble TNF receptor-2-IgG-Fc fusion protein (etanercept). These drugs
have some efficacy in some patients with rheumatoid arthritis and have been shown to relieve
pain and reduce synovitis (Fioravanti et al., 2009; Grunke & Schulze-Koops, 2006). Although
these studies show promise for targeted anti-inflammatory therapies, they have not shown
consistent and clear clinical effects for OA (Thysen et al., 2015). There are also significant
limitations, such as pharmacokinetic barriers to the joint space from systemic circulation and a
short intra-articular dwell time of drugs within an osteoarthritic joint, requiring high systemic
doses or repeated intra-articular injections (Chevalier et al., 2009; Evans et al., 2013, 2014).

6

1.4 Gene therapy approaches for OA
Gene therapy is a technique that includes the delivery or modification of a gene for the
treatment or prevention of disease. Intra-articular gene therapy is an advantageous approach for
articular cartilage repair because it overcomes delivery barriers, allows for authentic posttranslational processing, and can provide long term expression of therapeutic gene products
(Evans et al., 2018). The strategy for gene therapy has been to use both viral and non-viral
vectors to deliver anti-inflammatory cytokines, proteinase inhibitors, and growth factors in vivo
and ex vivo. These factors have been shown to successfully inhibit cartilage degeneration and
inflammation within the joint, as well as promote cartilage repair in animals models of OA
(Evans et al., 2013, 2015).
Invossa™ (Tissuegene-C), the first gene therapy for OA, was approved in South Korea in
2017 (Cho et al., 2016). Allogeneic chondrocytes from an established cell line are ex vivo
transduced with a retrovirus to express TGF-β1 to enhance cartilage repair. The cells are
irradiated and mixed with non-transduced cells prior to intra-articular injection. However,
despite the success of this therapy, the South Korean approval has been revoked and a Phase III
trial in the United States has been suspended due to contamination of the allogeneic cell line with
HEK293 cells (Evans, 2019). Gene therapy approaches delivering anti-inflammatory mediators
are also being explored. There are several clinical trials delivering IL-1Ra (Evans et al., 2005; P.
Wehling et al., 2009) or etanercept (Mease et al., 2009, 2010) to patients with rheumatoid
arthritis, and a Phase I clinical trial is ongoing for IL-1Ra delivery for OA (NCT02790723)
(Evans et al., 2018). This approach uses a self-complementing adeno-associated virus (AAV),
7

serotype 2.5, which is capable of transducing the synovium and chondrocytes in vivo and has
shown efficacy in an equine model of OA (Frisbie et al., 2002; Watson et al., 2013).
Despite the potential for success of anti-cytokine drugs and gene therapy approaches,
there are currently no effective disease modifying treatments addressing both the symptoms and
structural changes of OA (Evans et al., 2018; Goldring & Berenbaum, 2015; Matthews &
Hunter, 2011). Additionally, the inability of these approaches to dynamically and spatially
control the delivery of biologic drugs is an important limitation. Anti-cytokine therapies are often
delivered at high doses, which may have significant off-target effects, including an increased
susceptibility to infection and certain autoimmune diseases (Ramos-Casals et al., 2008) as well
as limited tissue regeneration and repair (Kimmerling et al., 2015; Palacios et al., 2010).

1.5 Cartilage tissue engineering, stem cells, and synthetic
biology
Tissue engineering, which combines the appropriate scaffolds, cells, and biologic cues to
repair specific tissues, provides a promising strategy for repair of articular cartilage (Chung &
Burdick, 2008; Johnstone et al., 2013). There are various cell sources for cartilage tissue
engineering, including chondrocytes (Mauck et al., 2000), bone marrow derived stem
cells(Pittenger et al., 1999), adipose derived stem cells (Estes et al., 2010), embryonic stem cells
(Koay et al., 2007; J. Kramer et al., 2000), and induced pluripotent stem cells (Adkar et al., 2019;
Diekman et al., 2012a). Murine induced pluripotent stem cells (miPSCs) are an attractive option
for tissue engineering because they are a source of large numbers of precisely defined, patient8

matched cells and are capable of chondrogenic differentiation and OA disease modeling
(Diekman et al., 2012a; Willard et al., 2014).
To address limitations with current OA treatments, tissue engineering and gene therapy
approaches can be combined, creating cartilaginous tissue that is capable of replacing damaged
tissue while delivering therapeutic drugs to diseased joints. Furthermore, applying synthetic
biology approaches allows for the engineering of new biological systems that do not exist in
nature. Our lab has utilized these strategies and shown that miPSCs can be engineered to
autonomously produce anti-inflammatory mediators in the presence of inflammatory stimuli,
protecting tissue engineered cartilage from degradation. Brunger et al. used the CRISPR-Cas9
genome editing system to insert a therapeutic transgene under the control of an endogenous
promoter that is responsive to inflammation, such that, when inflammatory pathways were
activated in cells, an anti-cytokine would be produced (Brunger et al., 2017b). Additionally,
several groups have explored approaches for inflammation-driven therapeutic transgene
production. Rachakonda et al. created a self-limiting promoter construct containing a truncated
COX-2 promoter driving expression of anti-inflammatory IL-4. They showed reduction of
inflammation in IL-1β and TNF-α stimulated articular chondrocytes (Rachakonda et al., 2008).
Khoury et al. showed protection in a mouse model of OA by delivering a NF-κB inducible TNF
inhibitor with a recombinant AAV5 vector (Khoury et al., 2007).
These systems result in temporal control over therapeutic transgene production in
response to inflammation without exogenous inputs, which is an important advance for gene
therapies for OA. The ability to combine tissue engineering, gene therapy, and synthetic biology
approaches provides a promising paradigm for OA treatment in which damaged tissues within
9

diseased joints can be replaced while providing autonomous therapeutics for engineered and
native tissues.

1.6 MicroRNAs
MicroRNAs (miRNAs) are small, endogenous, non-coding RNAs that were first
discovered in 1993 in Caenorhabditis elegans (Lee et al., 1993). Since then, miRNAs have been
shown to be an abundant class of regulatory molecules in animals and plants, and are generally
conserved between closely related species and broadly amongst more distant species (Carrington
& Ambros, 2003; Ibáñez-Ventoso et al., 2008). They are one of the main classes of small
regulatory RNAs of RNA interference (RNAi), a process that leads to silencing of gene
expression in eukaryotic cells. There have been increasing numbers of miRNAs deposited into
the miRBase online database for miRNAs since their discovery over 25 years ago. Currently,
there are 38,589 miRNAs in 271 organisms reported; 1978 mature miRNAs have been identified
in mice and 2654 have been identified in humans (Kozomara et al., 2019).
Biogenesis of miRNAs occurs first through the transcription of the primary miRNA
transcript (pri-miRNA) primarily by RNA polymerase II, which is at least 1000 nucleotides (nt)
long. Within the genome, miRNAs can be located intergenically and have their own independent
transcription units, or they can be within introns of genes and are processed from the introns
leading to coordinated expression of miRNAs and genes. While most miRNAs are isolated and
expressed as a single miRNA, miRNA clusters are arranged in close proximity and transcribed as
a polycistronic transcript and are often related to each other. Within the nucleus, the pri-miRNA
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is cleaved by Drosha, an RNase III endonuclease, and DiGeorge syndrome critical region gene 8
(DGCR8), forming a ~60-70 nt stem loop called the miRNA precursor (pre-miRNA). The premiRNA is transported to the cytoplasm via Ran-GTP and the Exportin-5 export receptor. In the
cytoplasm, the terminal base pairs and loop of the pre-miRNA are cleaved by another RNase III
endonuclease, Dicer. This results in short (21-25 nt), double-stranded RNA (dsRNA) called the
miRNA:miRNA* duplex and it consists of the mature miRNA and a passenger miRNA
(miRNA*) strands. The miRNA:miRNA* duplex is loaded into the RNA-induced silencing
complex (RISC)-loading complex as Dicer and a dsRNA-binding protein present the
miRNA:miRNA* duplex to Argonaute. Coincidentally, a helicase separates the dsRNA and the
miRNA* strand is discarded. The miRNA guides the RISC to the 3’ untranslated region (UTR)
of target mRNAs through full or partial complementary. mRNA binding is primarily determined
by complementarity of the seed sequence, which is positions 2-8 of the miRNA. The result of
this pairing is the repression of target mRNA translation, which occurs by mRNA degradation
and/or translation inhibition, although the exact mechanisms of translation inhibition are still not
completely understood (Bartel, 2004; Gebert & MacRae, 2019; Wilson & Doudna, 2013).
Because the seed region that directs miRNA targeting is only 7-8 nt, a miRNA can target
hundreds of genes, although the individual effect is relatively small (Selbach et al., 2008).
Furthermore, a single 3’ UTR can contain binding sites for multiple miRNAs. In this way,
miRNAs and miRNA clusters can regulate entire cellular pathways (Mestdagh et al., 2010;
Uhlmann et al., 2012).
More than 60% of protein coding genes have predicted binding sites for mRNAs
(Friedman et al., 2009), indicating that miRNAs play a critical role in the regulation of many
biological processes, such as development and cell proliferation, differentiation, and homeostasis
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(Gebert & MacRae, 2019). The deregulation of miRNAs is associated with many diseases,
particularly cancer, but also in neurological, cardiovascular, and musculoskeletal disorders
(Esteller, 2011). miRNAs are attractive therapeutic targets for complex diseases because of their
ability to target multiple genes and target pathways, as well as their unique expression dependent
on tissue, differentiation state, cell type, and disease state (Brown et al., 2007; Lagos-Quintana et
al., 2002; Landgraf et al., 2007). Thus, miRNAs are being explored in clinical trials for cancer
indications where strategies include the delivery of tumor suppressive miRNAs or the
suppression of oncomiRs through the delivery of miRNA mimics or inhibitors respectively.
Phase I and II clinical trials of miRNA therapeutics are also ongoing for other indications
including hepatitis C and type 2 diabetes with non-alcoholic fatty liver disease (Rupaimoole &
Slack, 2017).

1.7 microRNAs: cartilage development and homeostasis
miRNAs are important for regulating skeletal development, and have been shown to
participate in chondrogenesis, chondrocyte homeostasis, and osteoarthritis. Loss of miRNA
processing enzymes Dicer, Drosha, or DGCR8 in Col2a1 expressing cells (Col2a1-Cre; Dicerf/f)
results in severe skeletal growth defects, premature death in mice, and reduced growth plate
chondrocyte proliferation (T Kobayashi et al., 2015; Tatsuya Kobayashi et al., 2008).
Developmental defects were seen in mice with hemizygous deletion of Mir17hg, the gene that
encodes the miR-17~92 cluster. These mice have microcephaly, short stature, and digital
abnormalities which replicate the skeletal abnormalities of humans with mutations in this gene
who display features of Feingold syndrome (de Pontual et al., 2011). To determine the role of
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miRNAs in chondrocytes of developing human cartilage, differentially expressed miRNAs
between chondroprogenitor cells, differentiated chondrocytes, and hypertrophic were determined
using laser microdissection (McAlinden et al., 2013).
Individual miRNAs have also been shown to regulate chondrogenesis, chondrocyte
homeostasis, and osteoarthritis. miR-140 has been shown to be almost exclusively and highly
upregulated in chondrocytes (Tuddenham et al., 2006). Deletion of miR-140 resulted in a mild
skeletal phenotype in mice with a short stature and low body weight due to a reduction in
proliferating chondrocytes (Miyaki et al., 2010; Nakamura et al., 2011). These mice also
developed an age-related OA-like pathology and accelerated OA in a surgically induced murine
model, and transgenic mice with Col2a1 driven expression of pri-miR-140 were protected from
proteoglycan and type II collagen loss in an antigen-induced arthritis model (Miyaki et al.,
2010). Recently, patients were identified with a mutation in MIR140 gene, the gene that encodes
miR-140, leading to a heterozygous single nucleotide substitution in the first nt of the seed
sequence of miR-140-5p. The skeletal dysplasia in these patients was recapitulated in mice with
the corresponding mutation (Grigelioniene et al., 2019). miR-140 and a number of other
miRNAs modulate chondrogenesis in vitro. Sex Determining Region Y (SRY)-Box
Transcription Factor 9 (SOX9), the master regulator transcription factor for chondrogenesis, is
targeted by miR-145 and targets miR-29a. Delivery of these miRNAs results in inhibited
chondrogenic differentiation of mesenchymal stem/stromal cells (MSCs) (Guérit et al., 2014; Le
et al., 2016; Martinez-Sanchez et al., 2012; Yang et al., 2011). On the other hand, miR-140,
which targets HDAC4 and ADAMTS5, and miR-23b, which targets PRKACB, have been shown
to enhance chondrogenesis (Barter et al., 2015; Ham et al., 2012). These studies highlight the
importance of miRNAs in development, chondrogenesis, and chondrocyte homeostasis.
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1.8 microRNAs in OA
To determine the specific role of miRNAs in OA, a number of experiments have shown
differentially expressed miRNAs from OA affected tissues compared to normal cartilage
(Swingler et al., 2019). While many of these studies have focused on specific miRNAs, miRNAmRNA interactions, or mediators of OA related cartilage degeneration, a few early studies took
an unbiased approach for miRNA discovery. Jones et al. profiled the miRNAs in human knee
cartilage from OA and normal donors using a 157 miRNA qPCR panel (Jones et al., 2009) and
Miyaki et al. used a miRNA microarray to characterize the changes between normal and OA
human knee joints (Miyaki et al., 2009). Similarly, Iliopoulos et al. analyzed OA and healthy
cartilage using a miRNA microarray; however, they also integrated protein expression data and
clinical data to find miRNA-mRNA target pairs that may be controlling cartilage homeostasis
and degeneration (Iliopoulos et al., 2008). Since these studies, a number of groups have used
RNA-sequencing for a more in depth analysis of miRNAs in OA cartilage (Crowe et al., 2016;
Haseeb et al., 2017; Zheng et al., 2017) and some studies looked at the miRNA response to
inflammatory cytokines (Akhtar et al., 2010; Haseeb et al., 2017; Li et al., 2012; Rasheed et al.,
2016). These studies were critical in establishing the importance of miRNAs in OA, and many
miRNAs have been shown to be involved in cartilage protection and destruction (Endisha et al.,
2018). Several miRNAs have been consistently associated with OA and with functional target
gene validation and are summarized in Table 1.1 (adapted from Coutinho de Almeida et al.) (de
Almeida et al., 2017). However, these studies do not describe the complex regulatory
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mechanisms of miRNAs in OA, and thus, a number of studies are combining multiple -omics
techniques (Ratneswaran et al., 2020). One of the earliest studies of miRNAs in OA combined
transcriptomics and proteomics (Iliopoulos et al., 2008), and recently a study integrated miRNA
and mRNA sequencing data of preserved (macroscopically normal) and lesioned human OA
cartilage. The miRNA interactome that potentially regulates the chondrocyte transcriptome in
healthy or pathologic cartilage was revealed, and key miRNAs, miR-99a-3p and miR-143-5p,
and their target mRNAs were identified and functionally validated (Coutinho De Almeida et al.,
2019).

Table 1.1 Common OA associated miRNAs, their targets, and pathways.
miRNA

Target

Pathway

miR-140

ADAMTS5, MMP13, IGFBP5

Matrix degradation

miR-21

GAS5, GDF5

Autophagy

miR-449a

CL2A1, LEF-1, SIRT1

Chondrogenesis

miR-320

MMP13

Matrix degradation

miR-146a

VEGF. BCL-2, SMAD4, TGF-β

Chondrocyte apoptosis

miR-155-5p

SHIP1, CEBPB, IKBKE

Inflammation

miR-27a/b

IGFBP5, MMP13

Matrix degradation

miR-101

SOX9

Chondrogenesis and homeostasis

miR-23b

PPKACB

Chondrogenesis and homeostasis

miR-455-3p

ACVR2B, SMAD2, CHRDL1, TGF-β

Cartilage degradation
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While there is some overlap in miRNAs associated with OA, there are many that are not
agreed upon and even some miRNAs where differing effects are reported. Because OA is a
complex and heterogeneous disease with various etiologies, this discrepancy could be due to a
number of different reasons including stage of disease, body mass index, age, or location of
tissue harvest. Furthermore, the experimental set up for many of these studies differ with some
testing fresh cartilage while others isolate primary chondrocytes and culture in monolayer.
Additionally, experiments have varied sample sizes, dissimilar time courses, and use different
techniques and platforms for measuring miRNA expression levels.
The therapeutic potential of miRNAs has been explored in various in vivo animal models
of OA (Endisha et al., 2018; McAlinden & Im, 2018). In transgenic mice, cartilage-specific
expression of pri-miR-140 protected mice from antigen-induced arthritis (Miyaki et al., 2010)
and miR-146a global knockout suppresses spontaneous OA and reduced cartilage degeneration
in three different models of instability-induced OA (X. Zhang et al., 2017). Lentiviral delivery of
anti-miR-34a, si-miR-181b, miR-210, miR-222, and miR-483 via intra-articular injection has
also been shown to attenuate degeneration or delay progression of disease in various rat and
mouse OA models (Song et al., 2013, 2015; Wang et al., 2017; Yan et al., 2016; D Zhang et al.,
n.d.). Thus, miRNAs are important factors in the pathogenesis of OA, and understanding their
mechanisms of action provides an opportunity for novel OA therapies.

1.9 Summary
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The lack of effective therapies that address both the symptoms and structural changes in
OA remains a significant challenge. Cartilage tissue engineering, gene therapy, and synthetic
biology are promising approaches to overcome the limitations with current treatment options by
providing localized, controlled, and specific production of therapeutic mediators while replacing
damaged tissue. In this dissertation, miPSCs will be used for cartilage tissue engineering. First,
we will explore the ability of an inflammation-responsive circuit to autonomously produce an
anti-inflammatory mediator in the presence of inflammatory stimuli for spatiotemporal control of
transgene production without exogenous inputs. Second, this dissertation will describe the
dynamics of the transcriptomic changes that occur in response to inflammatory cytokines for a
better understanding of the molecular processes that drive OA and discovery of novel therapeutic
targets and mechanisms. Overall, the goal of this dissertation is to describe new tools and
strategies for improved cartilage tissue engineering which is necessary for replacement and
protection of OA cartilage.
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Chapter 2: A Synthetic Gene Circuit for SelfRegulating Delivery of Biologic Drugs in
Engineered Tissues
Partially adapted from: Pferdehirt, L., Ross, A. K., Brunger, J. M., & Guilak, F. (2019). A
synthetic gene circuit for self-regulating delivery of biologic drugs in engineered tissues. Tissue
Engineering Part A, 25(9-10), 809-820.

2.1 Abstract
Transient, resolving inflammation plays a critical role in tissue repair and regeneration. In
the context of joint disease, however, chronic inflammation following injury or with
osteoarthritis can lead to irreversible articular cartilage degradation and joint pain. Developing
tissue engineering strategies for the regeneration of articular cartilage remains challenging due to
the harsh inflammatory environment of an injured or arthritic joint, which can promote
degradation of engineered tissues as well as native articular cartilage. Here, we developed an
artificial gene circuit for controlled, cell-based delivery of biologic drugs, based on a nuclear
factor kappa-light- chain-enhancer of activated B cells (NF-κB)-responsive synthetic promoter.
Using lentivirus-based gene therapy, we engineered murine induced pluripotent stem cells
(iPSCs) capable of attenuating inflammation through controlled release of an anti-inflammatory
drug, interleukin-1 receptor antagonist (IL-1Ra), subsequently inhibiting gene circuit activation
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in a self-regulating manner. Murine iPSCs were transduced with the synthetic gene circuit either
in monolayer or through biomaterial-mediated transduction. Cells were maintained in monolayer
or differentiated into cartilage constructs and stimulated with different doses of interleukin 1
alpha (IL-1α) to determine the ability of this synthetic NF-κB responsive system to inhibit
inflammation and protect tissue-engineered constructs. In response to IL-1α, cells produced high
levels of IL-1Ra, which inhibited inflammatory signaling and protected tissue-engineered
cartilage from proteoglycan degradation. Our results show that the combination of gene therapy
and tissue engineering can be used to successfully create iPSCs capable of producing biologic
drugs in a controlled manner. This self-regulating system provides a tool for cell-based drug
delivery as the basis for a novel therapeutic approach for a variety of diseases.

2.2 Introduction
Osteoarthritis (OA) is a debilitating joint disease that causes severe pain and loss of joint
function, affecting over 32 million adults in the United States alone (Cisternas et al., 2016). OA
is characterized by the degeneration of articular cartilage, the hyaline cartilage that covers the
articulating surfaces of bones in diarthrodial joints. Because articular cartilage is avascular,
aneural, and alymphatic, it lacks an intrinsic ability to repair (Abramson & Attur, 2009). While
there are many risk factors for OA—including injury, aging, metabolic disorders, obesity, and
genetics—a common pathway for the pathogenesis and progression of joint degeneration and
pain involves the proinflammatory activity of several cytokines, particularly the interleukin-1
(IL-1) family of cytokines, including IL-1α and IL-1β, and tumor necrosis factor-α (TNF-α)
19

(Kapoor et al., 2011b). These cytokines primarily signal via the nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB) to induce extracellular matrix (ECM) degradation
through the inhibition of anabolic activities and enhanced production of degradative enzymes
and catabolic cytokines, particularly in articular chondrocytes (Rigoglou & Papavassiliou, 2013;
P. Wehling et al., 2009). Furthermore, inflammation can significantly inhibit repair of cartilage
and other joint tissues, as several studies have shown high sensitivity of stem cells and
engineered cartilage to cytokines such as IL-1 and TNF-α (McNulty et al., 2007; Moutos et al.,
2016; Ousema et al., 2012b; N. Wehling et al., 2009).
IL-1 receptor antagonist (IL-1Ra, anakinra), a competitive antagonist of IL-1, has been
shown to alleviate symptoms of rheumatoid arthritis (RA) and post-traumatic OA (Chevalier et
al., 2009; Choy et al., 2013; Furman et al., 2014b). Furthermore, several gene therapy approaches
to deliver IL-1Ra to the joints of patients with RA and OA are in progress or pending (Evans et
al., 2005, 2018; P. Wehling et al., 2009). However, despite the potential for success of anticytokine drugs and gene therapy approaches, there are currently no effective disease-modifying
treatments to address both the symptoms and structural change of OA (Evans et al., 2018;
Goldring & Berenbaum, 2015; Matthews & Hunter, 2011). Additionally, the inability of these
approaches to accomplish a sustained delivery of biologic drugs in a dynamically and spatially
controlled manner is an important limitation. Anti-cytokine therapies are often delivered at high
doses, which may have significant off-target effects, including an increased susceptibility to
infection and certain autoimmune diseases (Ramos-Casals et al., 2008), as well as limited tissue
regeneration and repair (Gopinath & Rando, 2008; Kimmerling et al., 2015; Mozzetta et al.,
2009). Therefore, the long-term success of stem cell–based therapies for cartilage repair or OA
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may require engagement of intrinsic cellular abilities to regulate the inflammatory environment
of the joint.
To address these limitations, tissue engineering and gene therapy approaches can be
combined to create a cartilaginous tissue that is capable of replacing damaged tissue while
delivering therapeutic drugs to diseased joints (Cucchiarini & Madry, 2019). Additionally, by
using both gene delivery and synthetic biology, cells can be transduced ex vivo with expression
vectors designed to produce a desired gene through specific inputs (Ausländer & Fussenegger,
2016; Madry et al., 2011). Furthermore, the implantation of tissue-engineered constructs allows
for localized delivery of biologic drugs to specific sites in the body.
The overall goal of this study was to create self-regulating (i.e., feedback-controlled)
stem cells capable of attenuating inflammation in a prescribed manner for a controlled release of
anti-inflammatory molecules. We engineered a synthetic transcriptional regulator system capable
of producing a therapeutic drug and packaged it into a lentiviral vector to allow for transduction
into various cell types and through different transduction strategies. Specifically, we developed
an NF-κB-inducible synthetic promoter that controls the release of a biologic drug, IL-1Ra, to
maintain tissue homeostasis in response to the activation of NF-κB in a long-term and sustained
manner (Figure 2.1). We utilized this lentiviral vector to create murine induced pluripotent stem
cells (iPSCs) capable of sensing and responding to inflammation. Additionally, we show the
proof-of-concept for site-specific, scaffold-mediated delivery (Brunger et al., 2014; Gersbach et
al., 2007) of this lentivirus to iPSCs. The transduced iPSCs were chondrogenically differentiated
into articular cartilage tissue to determine the efficacy of this vector in protecting engineered
tissue against cytokine- induced degradation. We hypothesized that this NF-κB-inducible
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biologic drug delivery system will allow for controlled, self-regulating production of antiinflammatory molecules in direct response to dynamic changes in inflammatory stimuli. This
type of cell-based approach could provide an effective method to treat OA and chronic
inflammatory diseases while overcoming limitations of current drug delivery techniques.

Figure 2.1 Overview of synthetic promoter design and experimental approach. A synthetic
promoter was designed with five NF-κB recognition motifs upstream of IL-1Ra to create an
NF-κB inducible promoter. The EF1α constitutive promoter was used to drive continuous
expression of IL-1Ra. iPSCs were transduced with lentivirus containing an NF-κB inducible
promoter that drives expression of IL-1Ra. In the presence of IL-1α, the synthetic promoter is
activated and produces IL-1Ra, preventing IL-1α from binding to the IL-1 receptor and
inhibiting activation of inflammatory cascades within the cell.
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2.3 Materials and Methods
2.3.1 Overall Strategy

The overall strategy for this work was to create a synthetic transcription system that is
activated by inflammatory cytokines and, when incorporated into a lentiviral vector, can be
readily delivered to different types of cells for applications in cell therapy or tissue engineering.
Cells transduced by the lentiviral vectors were programmed to express anti-inflammatory
biologic drugs downstream of the synthetic promoter, providing a negative feedback system that
blocks the action of an inflammatory cytokine (Figure 2.1). Here, we specifically tested the
ability of our synthetic transcription system to protect engineered cartilage from its intrinsic
response to inflammatory cytokines through three different methods: in monolayer, in tissueengineered cartilage, and with biomaterial-mediated delivery of vectors.

2.3.2 Vector Design

A synthetic NF-κB-inducible promoter was designed to incorporate multiple NF-κB
response elements that drive a target gene of interest (Brunger et al., 2017b). Briefly, a synthetic
promoter was developed containing five consensus sequences approximating the NF-κB
canonical recognition motif based on genes that are upregulated by inflammatory challenge:
InfB1, Il6, Mcp1, Adamts5, and Cxcl10 (Brunger et al., 2017b; Hou et al., 2002). Murine Il1rn or
firefly luciferase from the pGL3 basic plasmid (Promega) was cloned downstream of this
synthetic promoter; a TATA box derived from the minimal CMV promoter was cloned between
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the synthetic promoter and downstream target genes; and an NF-κB-negative regulatory element
(NRE-5’-AATTCCTCTGA-3’) (Nourbakhsh et al., 1993) was cloned upstream of the promoter
to reduce background signal (Figure 2.1). This engineered NRE-IL1Ra cassette results in
transgene expression when the promoter is activated in response to NF-κB-based inflammatory
stimuli, resulting in a ‘‘self-regulating’’ system. A constitutive control vector was also tested
using murine Il1rn cloned into the lentiviral transfer vector (No. 12250; Addgene) downstream
of the EF1α promoter sequence (Wiznerowicz et al., 2006) (EF1α-IL1Ra) using Gibson
Assembly (Gibson et al., 2009). A nuclear-targeted green fluorescent protein (GFP) (Kanda et
al., 1998) (No. 11680; Addgene) was cloned into a constitutive, lentiviral vector (Szulc et al.,
2006) (No. 11645; Addgene) and was used as a transduction control (GFP).

2.3.3 Lentivirus Production

HEK293T cells were co-transfected with an expression transfer vector, second-generation
packaging plasmid psPAX2 (No. 12260; Addgene), and an envelope plasmid pMD2.G (No.
12259; Addgene) by calcium phosphate precipitation to make vesicular stomatitis virus
glycoprotein pseudotyped lentivirus (Salmon & Trono, 2007). The expression transfer vectors
include the NRE-IL1Ra, NRE- Luc, EF1α-IL1Ra, and GFP plasmids. The lentivirus was stored
at -80°C until further use. The functional titer of each virus group was determined via
quantitative real-time polymerase chain reaction to determine the number of lentiviral DNA
copies integrated into the genome of transduced HeLa cells (Salmon & Trono, 2007).
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2.3.4 Cell Culture and Differentiation

Murine iPSCs, generated from tail fibroblasts from adult C57BL/6 mice and validated for
pluripotency as described by Diekman et al. (Carey et al., 2009; Diekman et al., 2012a), were
maintained on mitomycin C-treated mouse embryonic fibroblasts (Millipore). To track
inflammatory activity in cells, an iPSC reporter cell line was created via the CRISPR-Cas9
genome editing system to incorporate firefly luciferase downstream of the Ccl2 locus (Ccl2-Luc)
(Brunger et al., 2017b). In this cell line, proinflammatory signaling activates Ccl2 promoter
activity, resulting in the transcription of luciferase (Hao & Baltimore, 2009).
Unedited and Ccl2-Luc cells were then differentiated toward a mesenchymal state using a
high-density micromass culture. Differentiation medium contained Dulbecco’s modified Eagle’s
medium high glucose (DMEM-HG); 1% culture medium supplement containing recombinant
human insulin, human transferrin, and sodium selenite (ITS+); minimum essential medium
(MEM) nonessential amino acids; 55 mM 2-mercaptoethanol; 24 ng/mL gentamicin; 50 mg/mL
L-ascorbic acid; and 40 mg/mL L-proline. On days 3–5, this medium was supplemented with
100nM dexamethasone and 50ng/mL bone morphogenetic protein 4 (BMP-4; R&D Systems)
(Diekman et al., 2012a). After 15 days of culture, the micromasses were dissociated with pronase
and collagenase type II and the predifferentiated iPSCs (PDiPSCs) were plated on gelatin-coated
dishes in expansion medium containing DMEM-HG, 10% fetal bovine serum, 1% ITS+, MEM
nonessential amino acids, 55 mM 2-mercaptoethanol, 1% penicillin/streptomycin, 50 mg/mL Lascorbic acid, 40 mg/mL L-proline, and 4 ng/mL of basic fibroblast growth factor (bFGF; R&D
Systems). These cells were then expanded, transduced, and either used for monolayer
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experiments or in pellet cultures to produce engineered cartilage to evaluate the ability of these
cells to protect against inflammation.

2.3.5 Lentiviral Transduction and Culture of PDiPSCs

For initial characterization, PDiPSCs were transduced with the NRE-Luc virus. For all
other monolayer experiments, passage 4 PDiPSCs and Ccl2-Luc cells were transduced with
NRE-IL1Ra and EF1α-IL1Ra virus, and non-transduced (NT) cells were used as control.
In pellet experiments, PDiPSCs were transduced at passage 1 with NRE-IL1Ra, EF1αIL1Ra, or GFP virus. Passage 1 cells were trypsinized, and pellet cultures were created by
centrifuging 250k cells at 200xg for 5 min. The pellets were cultured in chondrogenic media
containing DMEM-HG, 1% ITS+, MEM nonessential amino acids, 55 mM 2-mercaptoethanol,
1% penicillin-streptomycin, 50 mg/mL L-ascorbic acid, 40 mg/mL L-proline, 100 nM
dexamethasone, and 10 ng/mL transforming growth factor-β3 (TGF-β3) for 21 days (Diekman et
al., 2012a).
For all monolayer and pellet studies, transduction media consisted of expansion medium
supplemented with 4 mg/mL polybrene (Sigma-Aldrich) and the desired number of viral
particles to achieve a multiplicity of infection = 3. Transduction media were exchanged with
expansion medium after 24 hours of transduction.
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2.3.6 Biomaterial-mediated Delivery

Biomaterial-mediated lentiviral transduction was tested using a model system based on
poly(ε-caprolactone) (PCL; molecular weight 70,000–90,000; Sigma-Aldrich), a scaffold
material commonly used for cartilage tissue engineering (W.-W. Hu, Elkasabi, et al., 2009;
Moutos et al., 2010). PCL was dissolved in glacial acetic acid at a 10% wt/vol ratio. Tissue
culture-treated plates were coated with the dissolved PCL, and the acid was evaporated
overnight. The acid was quenched with 1N NaOH, washed with phosphate buffered saline
(PBS), and sterilized with an ethanol gradient. Plates were then incubated in 0.002% poly-Llysine (PLL) solution (Sigma-Aldrich). PLL was aspirated, and two groups of lentivirus (NREIL1Ra and EF1α-IL1Ra) or PBS for NT controls were added to the plates and allowed to
incubate for 4 hours at 37°C (Brunger et al., 2014; W.-W. Hu, Elkasabi, et al., 2009). After virus
immobilization, viral supernatant was aspirated, wells were washed with PBS, and passage 4
PDiPSCs and Ccl2-Luc control cells were plated in the wells. After an additional 3 days of
culture, the ability of these cells to respond to and attenuate inflammation was evaluated through
a luminescence activity assay, protein production, and gene expression analysis.

2.3.7 Inflammatory Challenge

To evaluate the response of the synthetic promoter to inflammatory cytokines, unedited
PDiPSCs transduced with NRE-Luc were challenged with 1 ng/mL IL-1α or 20 ng/mL TNF-α
and evaluated at 72 hours after challenge.
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To determine the sensitivity and kinetics of the synthetic promoter, all groups of Ccl2Luc and unedited PDiPSCs (NT, NRE-IL1Ra, and EF1α-IL1Ra) were evaluated at 0, 4, 12, 24,
and 72 hours post supplementation of media with 0.05, 0.1, 0.5, or 1 ng/mL IL-1α and removal
of bFGF. Control cells were cultured in the absence of IL-1α.
For characterizing the pellets’ response to inflammation, after 21 days of chondrogenic
culture, pellets were challenged with 0.5 or 1 ng/mL IL-1α and removal of TGF-β and
dexamethasone for 72 hours. Control pellets were cultured in the absence of IL-1α.

2.3.8 Inflammation Activity Assay

Luciferase activity from NRE-Luc transduced cells and Ccl2-Luc cells in all monolayer
experiments was measured using the BrightGlo Luminescence kit (Promega) and a Cytation5
plate reader (Biotek). Luciferase activity is reported as a fold change of IL-1α-stimulated cells
over control cells cultured without IL-1α (n = 4–6).

2.3.9 Gene Expression

Unedited PDiPSCs from monolayer studies and pellets were harvested for quantitative,
reverse transcription polymerase chain reaction (qRT-PCR) after inflammatory challenge (n=4).
Monolayer cells were rinsed in PBS, lysed in Buffer RL (total RNA purification; Norgen
Biotek), and stored at -80°C until RNA isolation. Pellets of engineered cartilage tissue were
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rinsed in PBS and stored at -80°C until RNA isolation. Pellets were homogenized using a
miniature bead beater. RNA isolation was carried out following the manufacturer’s protocol
(Norgen Biotek). Reverse transcription was performed using Superscript VILO complementary
DNA (cDNA) master mix (Invitrogen). qRT-PCR was performed using Fast SyBR Green master
mix (Applied Biosystems) following the manufacturer’s protocol. Primer pairs (Table 2.1) were
synthesized by Integrated DNA Technologies, Inc. Fold changes were calculated using the ΔΔCT
method and are shown relative to the 0 hour no cytokine, NT control samples for monolayer
experiments, or GFP pellets without cytokines. For samples with no amplification, CT threshold
was set to the cycle limit.

Table 2.1 qRT-PCR primer pair sequences for inflammation and cartilage matrix genes, as well
as transgene expression analysis.
Target

Forward primer

Reverse primer

r18s

5’-CGGCTACCACATCCAAGGAA-3’

5’-GGGCCTCGAAAGAGTCCTGT-3’

Ccl2

5’-GGCTCAGCCAGATGCAGTTAA-3’

5’-CCTACTCATTGGGATCATCTTGCT-3’

Il6

5’-AAGTGCATCATCGTTGTTCATACA-3’

5’-CGAACTTCGACACTGACAAGAAGT-3’

Col2a1

5’-TCCAGATGACTTTCCTCCGTCTA-3’

5’-AGGTAGGCGATGCTGTTCTTACA-3’

Acan

5’-GCATGAGAGAGGCGAATGGA-3’

5’-CTGATCTCGTAGCGATCTTTCTTCT-3’

Il1rn

5’-GTCCAGGATGGTTCCTCTGC-3’

5’-TCTTCCGGTGTGTTGGTGAG-3’

2.3.10 Enzyme-linked Immunosorbent Assays

Culture media were collected from all unedited PDiPSC monolayer and pellet samples
after inflammation challenge and stored at -20°C. IL-1Ra concentration was measured with
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DuoSet enzyme-linked immunosorbent assay (ELISA) specific to mouse IL-1Ra/IL-1F3 (n=4;
R&D Systems). Each sample was measured in technical duplicates. Absorbance was measured at
450 and 540 nm.

2.3.11 Biochemical Analysis of Pellet Cultures

After 72 hours of inflammatory challenge, pellets were washed with PBS and stored at 20°C until processing. Pellets were digested overnight in 125 mg/mL papain at 65°C for
biochemical analysis. DNA content was measured with PicoGreen assay (Thermo Fisher), and
total sulfated glycosaminoglycan (sGAG) content was measured using a 1,9-dimethylmethylene
blue assay at 525 nm wavelength (Farndale et al., 1986a) (n=4).

2.3.12 Histological Processing of Pellet Cultures

After 72 hours of cytokine challenge, pellets were washed with PBS and fixed in 10%
neutral buffered formalin for 24 hours, paraffin-embedded, and sectioned at 8 mm thickness.
Slides were stained for Safranin-O/hematoxylin/fast green using a standard protocol (Estes et al.,
2010).

2.3.13 Statistical Analysis
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Statistical analysis was performed with the JMP Pro soft- ware package. Luminescence
data and biomaterial-mediated delivery qRT-PCR data were analyzed using analysis of variance
(ANOVA) with Dunnett’s post hoc test using NT as the control (α = 0.05). A two-way ANOVA
with Tukey’s HSD post hoc test was used to analyze all ELISA data, pellet biochemistry, and
pellet qRT-PCR data (α = 0.05).

2.4 Results
2.4.1 Responsiveness of the NF-κB synthetic promoter to IL-1α or TNF-α

PDiPSCs receiving the NRE-Luc vector responded to 1 ng/mL IL-1α and 20 ng/mL TNFα with a 10.17–0.54- and 8.40–0.32-fold increase in luminescence after 72 hours of cytokine
stimulation, respectively (Figure 2.2A).
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Figure 2.2 Evaluation of cells after cytokine stimulation in monolayer to determine
responsiveness of NRE-IL1Ra vector. (A) NRE-Luc cells were stimulated with 20 ng/mL TNFα or 1 ng/mL IL-1a and luminescence was measured after 72 hours. Bars represent the mean
relative luminescence units (RLU) ± SEM (n=4). (B) Fold change of NF-κB activity measured
by luminescence signal from Ccl2-Luc cells. Bars represent the mean fold change in RLU ±
SEM (n=6). Asterisks represent significance (p < 0.05) compared to NT control. (C) NT and
NRE-IL1Ra cells were treated with IL-1α and an ELISA was performed on samples to
determine IL-1Ra protein production. Values represent mean ± SEM (n=4). Groups not sharing
same letter are statistically significant (p < 0.05).
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2.4.2 Self-Regulating attenuation of inflammation by iPSCs

Attenuation of inflammatory signaling was tested in Ccl2-Luc reporter cells that produce
luciferase in response to inflammatory stimuli. After transduction, cells transduced with either
the NRE-IL1Ra or EF1α-IL1Ra lentivirus and NT control cells were treated with IL-1α at a
range of doses from physiologic (0.1 ng/mL) to supraphysiologic (1 ng/ mL) (McNulty et al.,
2007) and compared with cells without cytokine. In all doses of IL-1α, by 4 hours there was
significantly less luminescence output in both NRE-IL1Ra and EF1α-IL1Ra groups compared
with NT control. This trend was sustained up to 24 hours in all doses in the NRE-IL1Ra groups
and up to 72 hours in all doses except 0.05 ng/mL of IL-1α (Figure 2.2B) (p < 0.01). This
decrease in luminescence shows that there was attenuation of IL-1 signaling with the NREIL1Ra group and that this system is responsive at a range of cytokine concentrations.
To evaluate the ability of these vectors to produce therapeutic levels of IL-1Ra, unedited
PDiPSCs were lentivirally transduced with the NRE-IL1Ra or EF1α-IL1Ra vectors, and IL-1Ra
protein production was measured. The transduced cells and NT control cells were administered
with IL-1α and compared with cells without cytokine. Culture media were collected at 0, 4, 12,
24, and 72 hours to measure the production of IL-1Ra in response to an inflammatory challenge.
NRE-IL1Ra groups had an increase in IL-1Ra production over time and exhibited higher IL-1Ra
production with increased doses of IL-1α. There was a significant increase in IL-1Ra production
in the NRE-IL1Ra groups challenged with IL-1α compared with the NRE- IL1Ra cells without
cytokine at 24 and 72 hours (p < 0.0001) with 140.64–8.78 and 163.41–16.04 ng/mL IL-1Ra
produced with 0.5 and 1 ng/mL IL-1α stimulation at 72 hours, respectively. Additionally, there
was an increase in IL-1Ra in NRE-IL1Ra groups compared with the NT and EF1α-IL1Ra groups
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(Figure 2.2C and Figure 2.3A) (p < 0.0001). These results taken together show that this iPSCbased NRE- IL1Ra system responds to an inflammation challenge by producing increased levels
of the biologic drug.
A

B

Figure 2.3 IL-1Ra protein production in EF1α-IL1Ra group at different IL-1α doses over time
in (A) monolayer cells and (B) in monolayer cells transduced through biomaterial-mediated
delivery. Values represent mean ± SEM (n=4).

2.4.3 Transduced NRE-IL1Ra iPSCs from tissue-engineered cartilage is
protected from IL-1α

Following lentiviral delivery to iPSCs and 21 days of chondrogenic differentiation,
pellets were administered 0.5 or 1 ng/mL IL-1α for 72 hours and were compared with pellets that
did not receive cytokine. GFP control pellets showed rich Safranin-O staining for sGAG, one of
the primary components of cartilage ECM. Pellets treated with 0.5 ng/ mL or 1 ng/mL IL-1α for
72 hours displayed reduced Safranin-O staining (Figure 2.4A). Pellets made from NRE-IL1Ra
PDiPSCs produced 72.90–2.42 and 92.24–2.31 ng/mL IL-1Ra in response to 0.5 and 1 ng/mL
IL-1α, respectively, which was significantly higher than both GFP and EF1α-IL1Ra pellets (p <
0.0001). EF1α-IL1Ra pellets produced significantly higher levels of IL-1Ra compared with GFP
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Figure 2.4 Assessment of engineered cartilage to determine if NRE-IL1Ra protects tissues
from cytokine stimulation. (A) Safranin-O/fast green/hematoxylin stained tissue sections of
engineered cartilage (scale bar = 200µm). (B) IL-1Ra production collected from media samples
after IL-1α stimulation (n=4). Groups not sharing same letter are statistically significant (p <
0.05). (C) % conserved sGAG/DNA in pellets after addition of IL-1α (n=4). Groups not sharing
same letter are statistically significant (p < 0.05). (D) Relative gene expression compared to 0
hour control measured by qRT-PCR (n=4). Hash represents significance (p < 0.05).

control pellets (Figure 2.4B) (p < 0.001). NRE-IL1Ra pellets showed protection against IL-1αmediated matrix degradation, as indicated by robust Safranin-O staining and quantitative
biochemical analysis. NRE-IL1Ra pellets that received IL-1α had significantly higher amounts
of sGAG when normalized to the concentration of DNA in each pellet (normalized to pellets that
35

did not receive IL-1α) compared with EF1α-IL1Ra and GFP control pellets (Figure 2.4C) (p =
0.0322 and 0.0005, respectively). Despite the increased levels of IL-1Ra production, the EF1αIL1Ra pellets showed little or no inhibition of IL-1α-mediated sGAG loss, as indicated by the
loss of Safranin-O staining and sGAG/DNA content (Figure 2.4C).
Gene expression analysis of the pellets showed a significantly decreased expression of
inflammation-related genes, Ccl2 and Il6, in pellets engineered with the NRE-IL1Ra vector
compared with GFP control (p = 0.0164 and 0.0004, respectively) and EF1α-IL1Ra (p=0.0054
and 0.0008, respectively) pellets. Furthermore, NRE-IL1Ra pellets had significantly higher
levels of expression of cartilage matrix- related genes, Col2a1 and Acan, compared with GFP
control (p = 0.0088 and 0.0090, respectively) and EF1α-IL1Ra pellets (Figure 2.4D) (p = 0.0044
and 0.041, respectively).

2.4.4 Biomaterial-mediated lentiviral delivery shows self-regulating
production of IL-1Ra and attenuation of inflammation

Ccl2-Luc reporter cells were seeded on a PCL film and were transduced through
biomaterial-mediated delivery of either NRE-IL1Ra or EF1α-IL1Ra vectors. Cell were also
seeded on PCL without virus as a NT control. Cells were then administered with IL-1α. For all
doses of IL-1α, the NRE-IL1Ra group had significantly less luminescence out-put compared
with NT controls by 24 hours (p < 0.001) (Figure 2.5). At 72 hours post stimulation, NRE-IL1Ra
and EF1α- IL1Ra cells had decreased luminescent output compared with NT controls in all
doses, showing attenuation of inflammation (p < 0.0001).
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Figure 2.5 NF-κB activity of cells transduced via biomaterial-mediated lentiviral delivery.
Reported as fold change measured by luminescence signal from Ccl2-Luc cells. Bars represent
the mean fold change in RLU ± SEM of cells treated with IL-1α compared with controls
cultured with no cytokine (n=6). Asterisks represent significance (p < 0.05) compared to NT
control.

Culture media were collected at 0, 4, 12, 24, and 72 hours to measure IL-1Ra production
from cells transduced via biomaterial-mediated transduction. The NRE-IL1Ra group exhibited a
time- and dose-dependent response of IL-1Ra production. IL-1Ra protein production was
significantly increased at higher doses of IL-1α, with 139.31–19.6 and 165.91–15.83 ng/mL IL1Ra being produced when stimulated with 0.5 and 1 ng/mL IL-1α, respectively, at 72 hours (p <
0.001). Additionally, IL-1Ra production was increased in the NRE-IL1Ra group compared with
NT and EF1α-IL1Ra groups (Figure 2.6A and Figure 2.3B) (p < 0.0001). There was an increase
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A

B

Figure 2.6 Transgene induction in cells transduced via biomaterial-mediated lentiviral delivery.
(A) NT and NRE-IL1Ra cells were treated with IL-1α and an ELISA was performed on samples
to determine IL-1Ra protein production. Values represent mean ± SEM (n=4). Groups not
sharing same letter are statistically significant (p < 0.05). (B) Il1rn gene expression. Fold
changes were determined relative to 0 hour NT cells without cytokine. Error bars represent
means of fold change ± SEM (n=6).
in Il1rn gene expression in all cells that received the NRE-IL1Ra vector at 24 hours (Figure
2.6B), and in EF1α-IL1Ra cells at 0, 12, and 24 hours (Figure 2.7C). By 72 hours, NT and NREIL1Ra groups were not significantly different from each other, indicating that a decreased
inflammatory signaling led to an autoregulated decrease in Il1rn gene expression due to IL-1Ramediated inhibition of inflammation and subsequent gene circuit activation.
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Figure 2.7 Relative gene expression of cells transduced through biomaterial-mediated delivery
and challenged with IL-1α for the EF1α-IL1Ra group. Fold changes were determined relative
to 0 hour controls. Error bars represent means of fold change ± SEM (n=6). Asterisks represent
significant relative to NT control group (p < 0.05). (A) Ccl2 gene expression. (B) Il6 gene
expression. (C) Il1rn gene expression.
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Figure 2.8 Gene expression of cells transduced through biomaterial-mediated delivery and
challenged with IL-1α. Fold changes were determined relative to 0 hour NT cells without
cytokine. Error bars represent means of fold change ± SEM (n=6). Asterisks represent
significance relative to NT control group (p < 0.05). (A) Ccl2 gene expression. (B) Il6 gene
expression.
Gene expression analysis showed a dose-dependent increase in inflammation-related
genes, Ccl2 and Il6, as early as 4 hours following the delivery of inflammatory cytokines to all
groups of cells, which persisted through 72 hours. However, the biomaterial-mediated delivery
of the self-regulating NRE-IL1Ra compared with NT controls significantly decreased the
expression of Ccl2 starting at 4 hours and was maintained through 72 hours (Figure 2.8A) (p <
0.01). Ccl2 was also decreased in EF1α-IL1Ra cells compared with NT controls at 24 and 72
hours (Figure 2.7A). Il6 was significantly decreased in NRE-IL1Ra cells from 4 hours through
24 hours (Figure 2.8B) (p < 0.0001) and was significantly decreased in EF1α-IL1Ra cells at 24
hours (Figure 2.7B). Together, these results show that this system responds to inflammatory
stimulus and suggests that the therapeutic levels produced could inhibit inflammation.
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Additionally, these findings show a successful proof-of-concept experiment for the delivery of
either our transduced cells for implantation into the joint (Brunger et al., 2014; Glass et al.,
2014b; Moutos et al., 2016) or of our gene therapy vectors for transduction of endogenous cells
in vivo.

2.5 Discussion
A significant challenge in the field of regenerative medicine has been the ability to tissueengineer cartilage that is capable of withstanding the harsh inflammatory environment of an
injured or arthritic joint. We developed an iPSC-based lentiviral system in which cells sense and
respond to inflammatory stimuli by producing anti-inflammatory mediators. Using a
combination of regenerative medicine, synthetic biology, and gene therapy, we developed selfregulating iPSCs that are capable of forming engineered cartilage for the replacement of diseased
tissue and mitigating the inflammatory effects of IL-1α (Diekman et al., 2012a). Additionally,
the versatility of both the iPSCs and the lentiviral system allows for translation to various cell
types or tissues. Lastly, by leveraging the flexibility of lentiviral transduction in tissue
engineering applications, we demonstrated proof-of-concept of a targeted delivery method
allowing for spatial control of therapy via biomaterial-mediated lentiviral transduction.
Using lentivirus-based gene therapy, we engineered iPSCs with the NRE-IL1Ra vector,
creating a system that can dynamically respond to and attenuate NF-κB signaling. Cells receiving
the NRE-IL1Ra vector responded rapidly to IL-1α as all groups had reduced inflammatory
signaling by 4 hours after stimulation. Importantly, NRE-IL1Ra cells responded to both
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physiologic and supraphysiologic doses of IL-1α, and this response was sustained throughout 72
hours for all doses, except 0.05 ng/mL IL-1α. In addition, all doses of IL-1α activated the
synthetic promoter to produce therapeutic levels of IL-1Ra by 24 and 72 hours and in a dosedependent manner. This dose response provides a controlled production of the therapeutic drug
in response to different levels of inflammation. Cells that received the EF1α-IL1Ra vector
produced IL-1Ra, however, at a significantly lower amount than the NRE-IL1Ra vector. This
could be due to the low production of the transgene from the constitutive promoter, which has
previously been reported in lentiviral systems with constitutive reporters (Norrman et al., 2010).
An important advance of this work is the application of our lentiviral system in iPSCs.
iPSCs are attractive for tissue engineering and regenerative medicine because they can be
expanded, patient-matched, and differentiated into a variety of different cell types to treat
multiple tissues, overcoming the limitations of other common cell sources (Diekman et al.,
2012a; Willard et al., 2014). Here, we show that the NRE-IL1Ra vector can be delivered to
PDiPSCs, and these cells can form cartilaginous tissues, and that in the presence of 0.05 or 1
ng/mL IL-1α, engineered cartilage pellets produced high levels of IL-1Ra. This indicates the
potential use of this system for the repair of diseased articular cartilage and mitigation of
inflammation through a soluble release of IL-1Ra into the joint. We observed less IL-1Ra
production from tissue-engineered cartilage than cells in monolayer. This difference can be
attributed to the different differentiation states of the cells, as well as their accessibility to the
culture media. In pellets, cells are embedded within a dense ECM, which may bind or hinder the
transport of IL-1Ra and/or IL-1α (Fetter et al., 2006). Despite these transport limitations, NREIL1Ra pellets were protected from IL-1α-mediated degradation, as evidenced by rich Safranin-O
staining and significantly higher levels of sGAG/ DNA. Furthermore, NRE-IL1Ra pellets had
42

decreased expression of inflammation-related genes, while cartilage matrix-related genes were
sustained, showing the attenuation of inflammatory pathways and protection of the matrix.
In previous approaches, gene therapy for the treatment of OA has been performed with
plasmid DNA (Shea et al., 1999), retrovirus (Phillips et al., 2008), lentivirus (Gouze et al., 2002;
Kato et al., 2005; Yin et al., 2002), and most commonly non-integrating viral vectors such as
adeno-associated virus (Basile et al., 2008; W.-W. Hu, Elkasabi, et al., 2009; W.-W. Hu, Lang, et
al., 2009; W. Hu et al., 2008; W. W. Hu et al., 2007). Lentiviral delivery is advantageous for this
system due to its ability to stably integrate into the genome of dividing and non-dividing cells for
long-term gene expression, its larger packaging capacity, low immunogenicity, and low
cytotoxicity (Kumar et al., 2001; Wiznerowicz & Trono, 2005). The vector used in this study is
self-inactivating and, therefore, replication-defective, overcoming safety concerns previously
associated with viral gene therapy (Milone & O’Doherty, 2018; Schambach & Baum, 2008;
Zufferey et al., 1998). Additionally, our group and others have shown that viral vectors can be
immobilized to biomaterial surfaces or scaffolds for the delivery of therapeutic vectors to cells
(Brunger et al., 2014; Gersbach et al., 2007; Glass et al., 2014b; Moutos et al., 2016; Valonen et
al., 2010). Our study showed that biomaterial-mediated delivery of NRE-IL1Ra from PCL
provided efficient transduction and effectively decreased inflammatory signaling. Specifically,
biomaterial-mediated transduction of NRE-IL1Ra significantly decreased the expression of
inflammation-related genes, Ccl2 and Il6, and stimulated high levels of IL-1Ra production in a
dose-dependent manner. These results indicate that this approach provides an effective method
for delivering therapeutic vectors and can be applied for broader tissue engineering applications.
This strategy could address limitations of existing gene therapy approaches such as the loss of
therapeutic transgene expression over time when using non-integrating delivery methods, lack of
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spatial control of transduction when using systemic injections of vectors, and lack of controllable
or inducible production of transgenes when using constitutive expression vectors.
Previously, investigators have developed various systems for inflammation-inducible
expression of pro-regenerative or anti-inflammatory transgenes. Rachakonda et al. created a selflimiting promoter construct that was based on truncated promoter sequences of cyclooxygenase2 upstream of IL-4 to express IL-4 only in the presence of inflammation (Rachakonda et al.,
2008). Others have also created expression systems based on NF- κB binding sequences for
luciferase reporting vectors (Badr et al., 2009; Van de Loo et al., 2004) or inducible systems
driving the expression of anti-inflammatory mediators in adeno-associated viral vectors
(Adriaansen et al., 2007; Khoury et al., 2007). Previous work in our lab utilized CRISPR-Cas9
technology to genome-engineer stem cells capable of using the endogenous systems within the
cells to sense inflammation and produce therapeutic transgenes (Brunger et al., 2017b). While
this system has specific advantages in terms of the precision of CRISPR-based gene editing, by
packaging our NRE-IL1Ra system into a lentiviral expression cassette, we expand the vector’s
applicability to transduce different cell types and tissues, such as mesenchymal stem cells,
adipose-derived stem cells, or primary cells such as articular chondrocytes or synovial cells, all
of which are commonly used in tissue engineering or targeted for gene therapy but are more
challenging to edit with CRISPR-Cas9. The sensitivity of the synthetic promoter can be tuned
dependent on the sequence, number of tandem repeats, and neighboring regulatory elements, as
well as through gene editing (Brunger et al., 2017a) or epigenetic modification (Farhang et al.,
2017) of the cells’ receptors. Additionally, other inflammatory cytokines, such as TNF-α, or
intracellular signaling components can be targeted for specific or broad inhibition of
inflammation.
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Our synthetic lentiviral system can create self-regulating cells capable of sensing and
responding to inflammation with a therapeutic level of biologic drug. The continued
development of designer circuits through gene switches (Gossen & Bujard, 1992; Greber et al.,
2008; B. P. Kramer et al., 2004), microRNA classifiers (Wroblewska et al., 2015; Xie et al.,
2011), and synthetic transcription systems (Y. Y. Chen et al., 2010; Perez-Pinera et al., 2013; Qi
et al., 2013) provides a toolkit to engineer more complex circuits with specialized control. This
work adds to our long-term goals of developing a molecular toolbox (Ausländer & Fussenegger,
2013; Boyle & Silver, 2009) of biological building blocks for novel synthetic applications in
mammalian cells for ameliorating chronic diseases.
The autoregulatory capabilities of this system allow applications for regenerative
medicine or for use as a preventative approach to inflammatory disease. Applying this
methodology not only allows for protection against inflammation to aid in cartilage repair, but
also provides protection of any tissue-engineered constructs inserted to help repair an
osteoarthritic joint or biomaterial-mediated lentiviral transduction of any infiltrating cells
through localized transduction. The customization aspect of this system and its functionality in
monolayer, an engineered tissue replacement, and through scaffold-mediated delivery gives
innovative opportunities for effective treatments that are applicable in a variety of diseases.

2.6 Conclusions
We engineered a synthetic transcription system based on NF-κB signaling that can
attenuate the effects of the inflammatory cytokine IL-1α in a self-regulating manner. This system
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responds in a time- and dose-dependent manner to rapidly produce therapeutic levels of IL-1Ra.
The use of lentiviral gene therapy allows this system to be utilized through different transduction
methods and in different cell types for a variety of applications. Broadly, this approach may be
applicable in developing autoregulated biologic systems for tissue engineering and drug delivery
in a range of disease applications.
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Chapter 3: The miRNA-mRNA Interactome
of murine iPSC-derived Chondrocytes in
Response to Inflammatory Cytokines
Partially adapted from: Ross, A. K., Coutinho de Almeida, R., Ramos, Y.F.M., Li, J.,
Meulenbelt, I., & Guilak, F. (2020). The miRNA-mRNA Interactome of murine iPSC-derived
Chondrocytes in Response to Inflammatory Cytokines. Manuscript submitted for publication.

3.1 Abstract
Osteoarthritis (OA) is a degenerative joint disease, and inflammation within an arthritic
joint plays a critical role in disease progression. Proinflammatory cytokines, specifically IL-1
and TNF-α, induce aberrant expression of catabolic and degradative enzymes and inflammatory
cytokines in OA and result in a challenging environment for cartilage repair and regeneration.
microRNAs (miRNAS) are small, non-coding RNAs and are important regulatory molecules that
act by binding to target mRNAs to repress translation. miRNAs have been implicated in many
diseases, including OA. The goal of this study was to understand the mechanisms of miRNA
regulation of tissue engineered cartilage in response to IL-1β and TNF-α using an in vitro murine
induced pluripotent stem cell (miPSC) model system. We performed miRNA and mRNA
sequencing to determine the temporal and dynamic responses of genes to specific inflammatory
cytokines as well as miRNAs that are differentially expressed in response to both cytokines or
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exclusively to IL-1β or TNF-α. Through integration of mRNA and miRNA sequencing data, we
created networks of miRNA-mRNA interactions which may be controlling the response to
inflammatory cytokines. Within the networks, hub miRNAs, miR-29b-3p, miR-17-5p, and miR20a-5p, were identified. As validation of these findings, we showed that delivery of miR-17-5p
and miR-20a-5p mimics significantly decreased degradative enzyme activity levels while also
decreasing expression of inflammation-related genes in cytokine treated cells. This study utilized
an integrative approach to determine the miRNA interactome controlling the response to
inflammatory cytokines and novel mediators of inflammation-driven degradation in tissueengineered cartilage.

3.2 Introduction
Osteoarthritis (OA) is a debilitating joint disease that affects over 32 million adults in the
United States alone (Cisternas et al., 2016). OA is characterized not only by the degeneration of
articular cartilage, but also by subchondral bone thickening, osteophyte formation, and
modification of synovial fluid composition, which leads to joint pain, inflammation, and stiffness
(Goldring & Goldring, 2010). These processes are mediated in part by pro-inflammatory
cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α). These cytokines are
elevated in the synovial fluid, synovial membrane, subchondral bone, and cartilage of patients
with OA, and act by both suppressing synthesis of cartilage matrix components and inducing
expression of catabolic and degradative enzymes and inflammatory cytokines (BastiaansenJenniskens et al., 2017; Goldring & Otero, 2011; Kapoor et al., 2011a). The presence of
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inflammation within an OA joint provides a challenging environment for articular cartilage
repair, as pro-inflammatory cytokines will cause degeneration of native and tissue engineered
cartilage, as well as prevent chondrogenesis of stem cells (Ousema et al., 2012a; N. Wehling et
al., 2009).
Thus, a number of approaches have targeted the IL-1 or TNF-α pathways as a therapy for
OA (Fioravanti et al., 2009; Furman et al., 2014a; Grunke & Schulze-Koops, 2006; Kraus,
Birmingham, Stabler, Feng, Taylor, Moorman III, et al., 2012) or as a means of inhibiting
inflammatory effects on tissue-engineered cartilage (Brunger et al., 2017b; Glass et al., 2014a;
Moutos et al., 2016). Although these studies show promise for targeted anti-inflammatory
therapies, clinical studies have not shown consistent and clear effects on OA (Thysen et al.,
2015). Furthermore, although IL-1 and TNF-α use many shared signaling pathways and
mediators, it has been shown that they have distinct roles in OA. IL-1 plays a role in sustained
cell infiltration and cartilage destruction, while TNF-α is important for early joint swelling and
driving the inflammatory cascade (Joosten, 1999; Kapoor et al., 2011a). Because there are no
effective disease modifying treatments available that address both the symptoms and structural
changes of OA (Goldring & Berenbaum, 2015; Matthews & Hunter, 2011), a further
understanding of the molecular mechanisms regulating cartilage response to inflammation is
needed for the development of alternative therapeutic approaches.
In this regard, multiple studies suggest that interaction between microRNAs (miRNAs)
and mRNAs may play a critical role in the regulation of chondrocyte biology [reviewed e.g. by
Swingler et al. (Swingler et al., 2019) and by Asahara (Asahara, 2016)]. miRNAs are small,
endogenous, non-coding RNAs that play an important role in the regulation of many biological
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processes, such as proliferation, differentiation, and diseases including OA. They act by binding
to target mRNAs and repressing translation (Bartel, 2004). miRNAs have unique expression
profiles in different tissues, cell types, developmental stages, and diseases states (Brown et al.,
2007), and are attractive therapeutic targets because of their ability to regulate multiple genes
and target pathways in complex diseases. miRNAs have been shown to participate in
chondrogenesis, chondrocyte homeostasis, and osteoarthritis (Tatsuya Kobayashi et al., 2008;
McAlinden et al., 2013; Shen et al., 2017; Vicente et al., 2016). A number of experiments have
shown differentially expressed miRNAs from OA affected tissues compared to normal cartilage
(Crowe et al., 2016; Haseeb et al., 2017; Iliopoulos et al., 2008), and some have explored the
effects of IL-1β treatment on miRNA changes. However, these studies have not determined the
specific roles of miRNAs in regulating chondrocyte response to IL-1 or TNF-α while controlling
for factors such as stage of disease, body mass index, or location of tissue harvest (Shen et al.,
2017). The deregulation of miRNAs is an important factor in the pathogenesis of OA and
understanding their specific roles and regulatory networks in response to inflammatory cytokines
is important to guide miRNA-based therapies.
In a recent study, an integrative analysis of miRNA and mRNA sequencing data
comparing preserved (e.g., undamaged) and lesioned human osteoarthritic cartilage revealed the
miRNA interactome that potentially regulates the chondrocyte transcriptome in healthy or
pathologic cartilage (Coutinho De Almeida et al., 2019). Integration of RNA-sequencing data
allows for an unbiased and comprehensive study of the miRNA-mRNA interactions, which could
reveal previously unknown pathways or mediators in complex disease processes. Application of
this technique to chondrogenically-differentiated stem cells and tissue-engineered cartilage
would provide a better understanding of how tissues designed to replace damaged cartilage are
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going to respond within a diseased joint. Furthermore, induced pluripotent stem cells (iPSCs)
provide a source of large numbers of genetically-defined cells that are capable of chondrogenic
differentiation for cartilage repair or in vitro OA disease modeling (Adkar et al., 2017; Diekman
et al., 2012b; Willard et al., 2014).
The goal of this study was to determine the mechanisms of miRNA regulation of tissue
engineered cartilage in response to inflammatory cytokines using an in vitro murine induced
pluripotent stem cell (miPSC) model system previously developed in our lab (Diekman et al.,
2012b; Willard et al., 2014). This system also allows for the study of precise experimental
factors while controlling many parameters which have confounded other miRNA-based studies
(Cong et al., 2017), leading to few studies agreeing on key miRNAs and mechanisms of action.
We performed an integrative analysis of miRNA and mRNA sequencing data to functionally
characterize the miRNA regulatory networks driving IL-1β and TNF-α mediated responses of
tissue-engineered cartilage (Figure 3.1). We identify key miRNA mediators driving novel
mechanisms in the inflammatory response of articular chondrocytes and explore their ability to
attenuate inflammation in a miPSC model system of OA. This study provides a thorough
description of the miRNA-mRNA network following cytokine exposure, which can serve as the
basis for designing new therapies to prevent inflammation-driven degradation. Furthermore,
these findings can be applied to tissue engineering strategies for the treatment of OA, providing a
better understanding of the response of this tissue to the inflammatory environment of an OA
joint, such that therapies can be designed to improve replacement of damaged tissues and prevent
disease progression.
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Figure 3.1 Overview of experimental and analytical approach to determine the miRNAmRNA interactome of miPSC-derived cartilage in response to inflammation. miPSCs were
chondrogenically differentiated and then exposed to inflammatory cytokines, IL-1β or TNF-α,
for 4, 12, 24, and 72 hours and then analyzed by RNA-sequencing. Predicted and conserved
miRNA-mRNA interactions in which the miRNA and mRNA were differentially expressed
and had opposite direction of change of expression level from one time point to the next were
selected. MiRNA-mRNA pairs were further filtered for those that have been experimentally
validated, and miRNA interactomes were constructed.
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3.3 Materials and Methods
3.3.1 Cell Culture and Differentiation

Murine iPSCs (miPSCs), derived from mouse primary fibroblasts from adult C57BL/6
mice using a non-integrating system, were purchased from the Gates Center for Regenerative
medicine (University of Colorado, Denver). iPSCs were cultured in KnockOut™ Dulbecco’s
Modified Eagles Medium (DMEM) (Gibco), 20% lot-selected FBS (Atlanta Biologicals), 100
nM MEM nonessential amino acids (NEAA, Gibco), 55 µM 2-mercaptoethanol (2-me, Gibco), 2
mM Glutamax (Gibco), 1% penicillin/streptomycin (P/S, Gibco) and maintained on mitomycin
C-treated mouse embryonic fibroblasts (Millipore).
miPSCs were differentiated towards a mesenchymal state using a high-density micromass
culture (Diekman et al., 2012b). Differentiation medium contained DMEM-high glucose
(DMEM-HG, Gibco), 1% culture medium supplement containing recombinant human insulin,
human transferrin, and sodium selenite (ITS+, BD), 100 nM MEM NEAA, 55 µM 2-me, 24
ng/mL gentamicin, 50 µg/mL L-ascorbic acid, and 40 µg/mL L-proline. On days 3-5, this
medium was supplemented with 100 nM dexamethasone and 50 ng/mL bone morphogenetic
protein 4 (BMP-4, R&D Systems). After 15 days of culture, the micromasses were dissociated
with pronase (Millipore Sigma) and collagenase type II (Worthington Biochemical) and the predifferentiated iPSCs (PDiPSCs) were plated on gelatin-coated dishes in expansion medium
containing DMEM-HG, 10% lot-selected FBS, 1% ITS+, MEM NEAA, 55 µM 2-me, 1% P/S,
50 µg/mL L-ascorbic acid, 40 µg/mL L-proline, and 4 ng/mL of basic fibroblast growth factor
(bFGF, R&D Systems). Passage 2 PDiPSCs were pelleted by centrifugation of 250-300k cells
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and cultured for 21 days in chondrogenic medium consisting of DMEM-HG, 1% ITS+, 100nM
MEM NEAA, 55 µM 2-me, 1% P/S, 50 µg/mL L-ascorbic acid, 40 µg/mL L-proline, 100 nM
dexamethasone, and 10 ng/mL TGF-β3 (R&D Systems).

3.3.2 Inflammatory Challenge

After 21 days of chondrogenic culture, pellets underwent inflammatory challenge for 72
hours, which involved culture in chondrogenic media with 1 ng/mL IL-1β, 20 ng/mL TNF-α, or
control media without cytokines. TGF-β and dexamethasone were removed during this period.
To capture the short- and long-term responses of cells to inflammation, pellets were collected
after 4, 12, 24, and 72 hours, rinsed in PBS, and stored at -80ºC for RNA sequencing or at -20 ºC
for biochemical analysis.

3.3.3 RNA-sequencing

To extract RNA from tissue engineered cartilage, frozen pellets were homogenized with a
miniature bead beater. Total cellular RNA was isolated using the mirVana miRNA Isolation Kit
(Invitrogen) for small RNA sequencing or Total RNA Purification Plus Kit (Norgen) for mRNA
sequencing. Three pellets were pooled per sample and each sample was sequenced on an
Illumina HiSeq3000 (n=3). RNA-sequencing reads were trimmed (Trimmomatic (Bolger &
Giorgi, 2014), Cutadapt (Martin, 2011)), aligned (STAR aligner (Dobin et al., 2013) to map
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small RNA-sequencing reads to a custom murine miRNA database based on miRBase v22
(Kozomara et al., 2019) and RNA-sequencing reads to mm10 from Gencode vM15), counted
(featureCounts (Liao et al., 2014)), and only protein coding genes were included in downstream
mRNA sequencing analysis.

3.3.4 Differential Expression Analysis and miRNA-mRNA Network
Construction

The R package, DESeq2 (Love et al., 2014), was used to determine differentially
expressed miRNAs and genes through pairwise comparisons at each time point. Networks of
miRNA-mRNA interactions were constructed through the following selection criteria: 1.
conserved and predicted miRNA-mRNA target pairs (TargetScan Mouse release 7.2 (Agarwal et
al., 2015)); 2. differential expression (DE) at any time point (miRNA: padj < 0.05; mRNA: padj <
0.05, |log2(FoldChange)| > 1; padj is the false discovery rate computed by the BenjaminiHochberg multiple testing correction); 3. opposite direction of change of expression level
between time points for miRNA and mRNA; 4. miRNA-mRNA interaction is experimentally
validated (miRTarBase v7.0 (Chou et al., 2015) and TarBase v7 (Vlachos et al., 2014)
databases). K-means clustering was applied to the normalized counts (RPKM, reads per kilobase
per million mapped reads) of mRNAs differentially expressed at any time point in RStudio. The
number of clusters (5) was determined by the sum of squared error method. Enrichr (E. Y. Chen
et al., 2013; Kuleshov et al., 2016) was used for KEGG pathway analysis. Interactive networks
were visualized on a web application with the R package, Shiny (Chang et al., n.d.)
(https://guilaklab.shinyapps.io/validatednetwork/).
55

3.3.5 In vitro Experiments

Day 21 pellets were digested with collagenase type II and chondrocyte-like cells were
plated in monolayer in media containing DMEM-HG, 10% FBS, 1% ITS+, 100nM MEM
NEAA, 55 µM 2-me, 1% P/S. After 4 – 5 days, cells were transfected with mirVana miRNA
mimics and antagomirs (Invitrogen): controls [mimic (M), mimic Negative Control #1; inhibitor
(I), inhibitor Negative Control #1]; miR-29b-5p [M, MC10103; I, MH10103]; miR-17-5p [M,
MC12412; I, MH12412]; miR-20a-5p [M, MC10057; I, MH10057]. Lipofectamine RNAiMAX
Transfection Reagent (Invitrogen) was used according to manufacturer’s protocol and FBS and
P/S were removed from media prior to transfection. 24 hours after transfection, cells were
subject to an inflammatory challenge of 0.5 ng/mL IL-1β, 20 ng/mL TNF-α, or control media
without cytokines. Cell culture media was collected and stored at -20°C and cells were lysed
with buffer RL and stored at -80°C for analysis at 24 and 48 hours.

3.3.6 Histological and Biochemical Analysis of Pellet Cultures

After 72 hours of inflammatory challenge, pellets were washed with PBS and fixed in
10% neutral buffered formalin for 24 hours, paraffin embedded, and sectioned at 8 µm thickness.
Slides were stained for Safranin-O/hematoxylin/fast green (Estes et al., 2010).
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Pellets were digested overnight in 125 µg/mL papain at 65°C for biochemical analysis.
DNA content was measured with PicoGreen assay (Thermo Fisher) and total sulfated
glycosaminoglycan (sGAG) content was measured using a 1,9-dimethylmethylene blue assay at
525 nm wavelength (Farndale et al., 1986b).

3.3.7 Gene Expression Validation with Quantitative Real Time PCR

For mRNA gene expression analysis, isolated, total cellular RNA was reverse transcribed
using Superscript VILO cDNA master mix (Invitrogen). Quantitative, reverse transcription
polymerase chain reaction (qRT-PCR) was performed using Fast SYBR master mix (Applied
Biosystems) following the manufacturer’s protocol. Primer pairs were synthesized by Integrated
DNA Technologies, Inc.: Ccl2 [forward (F), 5’-GGCTCAGCCAGATGCAGTTAA-3’; reverse
(R), 5’-CCTACTCATTGGGATCATCTTGCT-3’]; Mmp13 [F, 5’GGGCTCTGAATGGTTATGACATTC-3’; R, 5’-AGCGCTCAGTCTCTTCACCTCTT-3’];
r18s [F, 5’-CGGCTACCACATCCAAGGAA-3’; R, 5’-GGGCCTCGAAAGAGTCCTGT-3’].
Data are reported as fold changes and were calculated using the ΔΔCT method and are shown
relative to the non-transfected control media group at each time point and ribosomal 18s is used
as the reference gene.

3.3.8 MMP Activity Assay
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MMP activity in culture media was measured by detecting the quenching of a fluorogenic
substrate Dab-Gly-Pro-Leu-Gly-Met-Arg-Gly-Lys-Flu (Sigma-Aldrich) (Wilusz et al., 2008).
Latent MMP’s were activated using p-aminophenylmercuric acetate and total MMP activity was
measured as the difference between a broad-spectrum MMP inhibitor, GM6001 (EMD
Biosciences Inc.) and a scrambled negative control peptide (EMD Biosciences Inc.) with
fluorescence measured at 485 nm excitation and 535 nm emission and is reported as relative
fluorescence units (RFU).

3.3.9 Statistical Analysis

Statistical analysis was performed with the JMP Pro software package. A two-way
ANOVA with Tukey’s HSD post-hoc test was used to analyze all biochemistry, qRT-PCR, and
MMP activity assay data (α = 0.05).

3.4 Results
3.4.1 Histological and biochemical response of tissue engineered cartilage to
inflammation

After 21 days of culture in chondrogenic media, the resulting cartilaginous pellets
showed a spherical shape, and pellets in control media without cytokines exhibited robust
safranin-O staining (Figure 3.2A). However, when treated with inflammatory cytokines, either 1
ng/ml of IL-1β or 20 ng/ml of TNF-α, pellets exhibited reduced Safranin-O staining by 72 hours,
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indicating a decrease in the primary cartilage extracellular matrix component, aggrecan (Figure
3.2A). Biochemical analysis by DMMB assay, normalized to dsDNA content, showed a
corresponding decrease in sulfated glycosaminoglycans (sGAGs) at 72 hours in groups receiving
IL-1β or TNF-α, as compared to the pellets in control media (Figure 3.2B).

A

B

Figure 3.2 Tissue level responses of miPSC-derived cartilage to inflammatory cytokines. At
each time point, (A) pellet sections were stained for Safranin-O/hematoxylin/fast green (scale
bar = 500μm) and (B) sGAG content was measured, normalized to DNA content per pellet
(mean±SEM; n=3). At each time point, differences among groups with different letters are
statistically significant (p<0.05).

3.4.2 Differentially expressed miRNAs and genes in response to inflammatory
cytokines

Day 21 pellets were subject to IL-1β and TNF-α inflammatory challenge and collected
for RNA-seq at 4, 12, 24, and 72 hours. The IL-1β or TNF-α stimulated pellets were compared
pairwise to control at all time points in order to determine differentially expressed (DE) miRNAs
and genes (mRNAs) at each time point. Over time, there were increasing numbers of DE
miRNAs and genes. From 4 to 72 hours following treatment, the number of significantly DE
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miRNAs increased from 4 (4 up-regulated, 0 down-regulated) to 86 (37 up-regulated, 49 downregulated) in IL-1β treated pellets and 4 (4 up-regulated, 0 down-regulated) to 168 (100 upregulated, 68 down-regulated) in TNF-α treated pellets (Figure 3.3A). Similarly, the number of
DE mRNAs from 4 to 72 hours increased from 772 (481 up-regulated, 291 down-regulated) to
1781 (849 up-regulated, 932 down-regulated) in IL-1β treated pellets and 612 (516 up-regulated,
96 down-regulated) to 1147 (635 up-regulated, 512 down-regulated) in TNF-α treated pellets
(Figure 3.3A).
A

B

C

Figure 3.3 Differential expression analysis of miRNAs and mRNAs. (A) The number of upand down-regulated miRNAs and mRNAs in response to IL-1β or TNF-α over time.
Distribution of shared or unique miRNAs or mRNAs (B) with each inflammatory cytokine
over time or (C) at each time point.
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While IL-1β and TNF-α groups shared the same DE miRNAs at 4 hours, over time there
was an increasing number of both shared miRNAs as well as miRNAs that were uniquely up- or
down-regulated with each cytokine. However, with respect to the mRNA transcriptome, we
identified many DE genes that were specific to each cytokine at early time points. At later times,
there were increasing numbers of shared and unique DE genes in response to either IL-1β or
TNF-α (Figure 3.3B). There were 348 shared, 424 IL-1β specific, and 264 TNF-α specific DE
genes at 4 hours, which increased to 560 shared, 1221 IL-1β specific, and 587 TNF-α specific
DE genes at 72 hours.
Analysis of the differentially expressed miRNAs over time showed that most of the
miRNAs that are expressed at early time points (4 and 12 hours) are also expressed at later time
points (24 and 72 hours) for both IL-1β and TNF-α treated groups (Figure 3.3C). On the other
hand, there were more differentially expressed genes unique to each time point in addition to the
genes that were differentially expressed at multiple time points (Figure 3.3C). Cluster analysis
revealed 5 unique expression profiles of genes over time for both IL-1β and TNF-α pellets
(Figure 3.4), and KEGG pathway analysis shows that each of these clusters are enriched for
different pathways (Appendix Tables 1 and 2). These results show that there are unique miRNA
and mRNA profiles with some overlapping genes and miRNAs, and others that are dependent on
IL-1β or TNF-α.
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Figure 3.4 Expression patterns of clusters of differentially expressed mRNAs. Points on
graph represent the scaled reads per kilobase per million mapped reads (RPKM) values for
the centers of each sample in the cluster (n=3).

Differential expression analysis reveals miRNAs that are differentially expressed
compared to controls at each time point (Figure 3.5). At 4 hours, miR-222-5p (IL-1β, TNF-α:
LFC (padj), 1.27 (1.6x10-18), 1.57 (8.3x10-30)) and -3p (IL-1β, TNF-α: LFC (padj), 0.84 (1.5x1012

), 0.72 (6.2x10-9)), miR-92a-1-5p (IL-1β, TNF-α: LFC (padj), 1.43 (1.2x10-7), 1.02 (2.5x10-3)),

and miR-155-5p (IL-1β, TNF-α: LFC (padj), 0.52 (2.3x10-3), 0.67 (2.2x10-6)) were up-regulated
in response to both IL-1β and TNF-α. At 72 hours, among the most highly upregulated miRNAs
in both IL-1β and TNF-α treated pellets were miR-146a-5p (IL-1β, TNF-α: LFC (padj), 3.05
(2.0x10-15), 4.10 (3.0x10-28)), miR-7a-5p (IL-1β, TNF-α: LFC (padj), 3.79 (7.6x10-3), 4.86
(1.1x10-4)), and miR-155-5p (IL-1β, TNF-α: LFC (padj), 1.57 (1.4x10-40), 1.43 (1.6x10-33)); those
most highly down regulated with both cytokines include: miR-341-5p (IL-1β, TNF-α: LFC (padj),
-2.53 (4.0x10-27), -1.85 (1.7x10-16)), miR-410-5p (IL-1β, TNF-α: LFC (padj), -1.81 (1.1x10-2), 1.82 (1.0x10-2)), and miR-665-3p (IL-1β, TNF-α: LFC (padj), -1.61 (8.0x10-11), -1.11 (1.5x10-5)).
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Several miRNAs were found to be regulated exclusively by IL-1β, such as miR-138-1-3p and
miR-154-3p (Figure 3.6A), or by TNF-α, such as miR-7678-3p, miR-6972-3p, miR-147-3p,
miR-210-5p, and miR-421-5p (Figure 3.6B). Similarly, differentially expressed genes were
visualized with volcano plots (Figure 3.7), and KEGG pathway analysis was conducted on
significant DE mRNAs at each time point to determine enriched pathways over time for both IL1β (Appendix Table 3) and TNF-α (Appendix Table 4) groups. The differentially expressed
mRNAs in response to both cytokines were significantly enriched for genes involved in TNF
signaling pathway, cytokine-cytokine receptor interaction, and IL-17 signaling pathways and
characterized by genes such as Ptgs2, Nfkb1 and 2, MMP’s, and chemokine CC and CXC
subfamily genes. Additional pathways of interest that were involved at various time points were
rheumatoid arthritis, protein digestion and absorption, and PI3K-Akt signaling pathways,
characterized by genes such as Tgfb3, MMP’s, Ccl2, and Col2a1 and other collagens.
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Figure 3.5 Volcano plot visualization shows miRNAs that are differentially expressed
compared to controls at each time point (red: padj < 0.05). LFC, log2(FoldChange).
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B

Figure 3.6 From RNA-sequencing analysis, fold changes of miRNAs that are differentially
expressed exclusively with (A) IL-1β or (B) TNF-α from RNA-sequencing analysis. LFC,
log2(FoldChange).
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Figure 3.7 Volcano plot visualization shows mRNAs that are differentially expressed
compared to controls at each time point (red: padj < 0.05, |LFC| > 1). LFC, log2(FoldChange).
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3.4.3 miRNA interactomes in response to inflammatory cytokines

To determine the functional roles that miRNAs have on predicted target genes, RNA and
small RNA-sequencing data sets were integrated such that networks could be constructed to
visualize relationships between miRNA-mRNA predicted target pairs that are conserved
(TargetScan database), contain a miRNA and mRNA that are each differentially expressed, and
whose levels of expression are changing in opposite directions from one time point to the next
(Figures 3.8 – 311). The total number of interactions increased over time in both the IL-1β and
TNF-α groups from 15 to 1059 and 1 to 1128, respectively. There were 550 genes and 49
miRNAs in the IL-1β network and 445 genes and 78 miRNAs in the TNF-α network at 72 hours.
Upon further filtering for only interactions that have been previously experimentally validated
from the miRTarBase or TarBase databases, the number of interactions within networks reduced
to 216 (153 genes and 28 miRNAs) in the IL-1β and 194 (128 genes and 24 miRNAs) in the
TNF-α network at 72 hours (Figure 3.12).
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Figure 3.8 IL-1β miRNA-mRNA interactome at (A) 4, (B) 12, and (C) 24 hours. Network of
conserved and predicted miRNA-mRNA target pairs that are differentially expressed, are
changing expression levels in opposite directions, and have been experimentally validated in
response to 1 ng/mL IL-1β. The color of the node indicates the LFC of the gene or miRNA
and the size of the node is proportional to the number of connections. The thickness of the
line corresponds to the context++ score from the TargetScan database. LFC,
log2(FoldChange).
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Figure 3.9 IL-1β miRNA-mRNA interactome at 72 hours: network of conserved and
predicted miRNA-mRNA target pairs that are differentially expressed, are changing
expression levels in opposite directions from 24 to 72 hours, and have been experimentally
validated in response to 1 ng/mL IL-1β. The color of the node indicates the LFC of the gene
or miRNA, and the size of the node is proportional to the number of connections. The
thickness of the line corresponds to the context++ score from the TargetScan database. LFC,
log2(FoldChange).
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Figure 3.10 TNF-α miRNA-mRNA interactome at (A) 12 and (B) 24 hours. Network of
conserved and predicted miRNA-mRNA target pairs that are differentially expressed, are
changing expression levels in opposite directions, and have been experimentally validated in
response to 20 ng/mL TNF-α. The color of the node indicates the LFC of the gene or miRNA
and the size of the node is proportional to the number of connections. The thickness of the
line corresponds to the context++ score from the TargetScan database. LFC,
log2(FoldChange).
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Figure 3.11 TNF-α miRNA-mRNA interactome at 72 hours: network of conserved and
predicted miRNA-mRNA target pairs that are differentially expressed, are changing
expression levels in opposite directions from 24 to 72 hours, and have been experimentally
validated in response to 20 ng/mL TNF-α. The color of the node indicates the LFC of the
gene or miRNA, and the size of the node is proportional to the number of connections. The
thickness of the line corresponds to the context++ score from the TargetScan database.
LFC, log2(FoldChange).
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Figure 3.12 The number of total and validated miRNA-mRNA interactions for IL-1β and
TNF-α following RNA- and small RNA-sequencing data integration.

To determine which miRNAs within the networks regulate the inflammatory responses,
KEGG pathway analysis was conducted on the genes within the networks including all
interactions (Tables 3.1 and 3.2). Genes in inflammation and OA related pathways (PI3K-AKt
signaling pathway, ECM-receptor interaction, cytokine-cytokine receptor interaction, MAPK
signaling, protein digestion and absorption, TNF signaling pathway JAK-STAT signaling
pathway, and IL-17 signaling pathway; Tables 3.1 – 3.3) were overlaid onto the network and
quantified the number of connections from each miRNA. Hub miRNAs, miR-17-5p and miR20a-5p and miR-29b-3p, were identified in both IL-1β and TNF-α networks and are potentially
controlling the miRNA response to these cytokines. miR-17-5p was connected to 52 genes (29
validated interactions) in the IL-1β network and 36 genes (21 validated interactions) in the TNFα network at 72 hours. miR-20a-5p was connected to 52 genes (23 validated interactions) in the
IL-1β network and 36 genes (17 validated interactions) in the TNF-α network at 72 hours. miR29b-3p was connected to 79 genes (30 validated interactions) in the IL-1β network and 54 genes
(23 validated interactions) in the TNF-α network at 72 hours. Inflammation and cartilage related
interactions with these hub miRNAs are listed in Table 3.3.
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Table 3.1 Enriched pathways of genes within the IL-1β network at 72 hours.
Pathway

P-value Genes

Lama3; Lamc2; Il6ra; Pik3cb; Lpar4; Thbs2; Fgf1; Egfr; Gys1;
PI3K-Akt
Fgf7; Reln; Gng2; Ibsp; Erbb4; Itgb8; Pdgfra; Hgf; Lamb1; Igf1;
1.3x10-9
Ngf; Pgf; Ereg; Col2a1; Kitl; Col6a2; Fgf18; Col9a1; Bcl2; Sgk3;
signaling pathway
Kras; Fgfr3; Creb5; Fgf10
Rap1 signaling
pathway

3.5x10

-7

Pdgfra; Prkcb; Hgf; Pik3cb; Lpar4; Igf1; Adcy1; Ngf; Fgf1; Egfr;
Pgf; Fgf7; Plcb4; Cnr1; Kitl; Fgf18; Kras; Rapgef5; Fgfr3;
Rapgef4; Fgf10

Focal adhesion

2.7x10-6

Pdgfra; Prkcb; Hgf; Lama3; Lamc2; Lamb1; Pik3cb; Igf1; Thbs2;
Egfr; Pgf; Mylk; Reln; Col2a1; Ibsp; Col6a2; Col9a1; Bcl2; Itgb8

ECM-receptor
interaction

2.7x10-6

Reln; Sv2c; Col2a1; Ibsp; Col6a2; Lama3; Col9a1; Itgb8;
Lamc2; Lamb1; Thbs2; Cd44

5.8x10-6

Epas1; Il23r; Lama3; Lamc2; Il6ra; Pik3cb; Lpar4; Adcy1; Fgf1;
Egfr; Fgf7; Gng2; Ednrb; Il13ra1; Fzd1; Pdgfra; Jag1; Prkcb;
Fzd4; Hgf; Lamb1; Igf1; Pgf; Runx1; Nfkbia; Bmp2; Plcb4; Kitl;
Fgf18; Bcl2; Kras; Il6st; Fgfr3; Fgf10

Pathways in
cancer

Protein digestion
Col17a1; Col15a1; Col27a1; Col2a1; Mme; Col11a1; Eln;
6.5x10-6
and absorption
Fxyd2; Col6a2; Col9a1; Atp1a2; Slc8a1
Cytokine-cytokine
Il21; Gdf10; Mstn; Il1r1; Il23r; Il34; Lif; Lifr; Il6ra; Tnfrsf11b;
receptor
2.1x10-5 Ngf; Acvr1b; Cxcl2; Cx3cl1; Cxcl10; Bmp3; Bmp2; Il18rap;
interaction
Tnfsf11; Il6st; Tnfrsf21; Il13ra1
cGMP-PKG
Oprd1; Mef2c; Kcnj8; Atp1a2; Adcy1; Adra2c; Slc8a1; Adra2a;
2.3x10-5
signaling pathway
Mylk; Nppc; Plcb4; Ednrb; Fxyd2; Adora1; Pde3a; Creb5
Insulin secretion

2.3x10-5

Rims2; Adcyap1; Plcb4; Prkcb; Fxyd2; Atp1a2; Cck; Kcnn3;
Adcy1; Rapgef4; Creb5

Pdgfra; Mef2c; Prkcb; Il1r1; Hgf; Igf1; Ngf; Dusp8; Fgf1; Egfr;
MAPK signaling
2.3x10-5 Pgf; Ereg; Cacna1g; Cacna1i; Fgf7; Erbb4; Kitl; Fgf18; Kras;
pathway
Fgfr3; Map3k5; Fgf10
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Table 3.2 Enriched pathways of genes within the TNF-α network at 72 hours.
Pathway

P-value Genes

Col18a1; Col15a1; Col27a1; Col11a1; Eln; Col22a1; Col11a2;
Protein digestion
1.1x10-12 Atp1b1; Slc8a1; Col1a1; Col3a1; Col1a2; Col2a1; Col5a1;
and absorption
Slc7a8; Col4a4; Col9a1; Col9a3
ECM-receptor
interaction

3.9x10-10

PI3K-Akt
2.2x10-9
signaling pathway

Itga2; Lamc2; Thbs2; Col1a1; Reln; Col1a2; Col2a1; Ibsp;
Col4a4; Itga11; Col9a1; Col9a3; Itgb7; Cd44; Itga9
Csf1r; Csf1; Pdgfb; Lamc2; Lpar4; Thbs2; Fgf7; Reln; Ibsp;
Itgb7; Itga2; Vegfc; Ngf; Prlr; Ereg; Vegfa; Col1a1; Col1a2;
Col2a1; Ppp2r2c; Col4a4; Itga11; Ddit4; Col9a1; Col9a3; Fgfr3;
Met; Creb5; Itga9

Focal adhesion

Cav3; Itga2; Pdgfb; Vegfc; Lamc2; Parvb; Thbs2; Vegfa;
4.0x10-9 Mapk10; Col1a1; Reln; Col1a2; Col2a1; Ibsp; Col4a4; Itga11;
Col9a1; Col9a3; Itgb7; Met; Itga9

TNF signaling
pathway

1.6x10-7

Human
papillomavirus
infection

Notch3; H2-q7; Lamc2; Thbs2; Prkcz; Reln; Ibsp; Itgb7; Ikbke;
5.8x10-7 Fzd2; Fzd4; Itga2; Fzd8; Vegfa; Col1a1; Col1a2; Col2a1;
Ppp2r2c; Col4a4; Irf1; Itga11; Col9a1; Col9a3; Creb5; Itga9

Transcriptional
misregulation in
cancer

7.6x10-7

Csf1r; Arnt2; Cebpb; Mef2c; Gadd45a; Igfbp3; Hmga2; Etv1;
Traf1; Etv5; Dusp6; Nr4a3; Tspan7; Bmp2k; Itgb7; Erg; Met

Arrhythmogenic
right ventricular
cardiomyopathy
(ARVC)

4.2x10-6

Cacng8; Gja1; Cacnb3; Des; Itga2; Itga11; Dmd; Itgb7; Slc8a1;
Itga9

Hypertrophic
cardiomyopathy
(HCM)

2.1x10-5

Cacng8; Edn1; Cacnb3; Des; Itga2; Itga11; Dmd; Itgb7; Slc8a1;
Itga9

2.8x10-5

Camk2b; Csf1r; Notch3; Pdgfb; Cxcr4; Lamc2; Lpar4; Adcy1;
Fgf7; Egln1; Arnt2; Egln3; Edn1; Fzd2; Gadd45a; Fzd4; Txnrd1;
Itga2; Fzd8; Vegfc; Traf1; Vegfa; Mapk10; Bmp2; Traf4; Col4a4;
Fgfr3; Met

Pathways in
cancer

Cebpb; Edn1; Csf1; Ccl20; Lif; Tnfaip3; Traf1; Tnfrsf1b; Cxcl2;
Cx3cl1; Mapk10; Cxcl10; Irf1; Creb5
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Table 3.3 Inflammation and cartilage related genes* connected to hub miRNAs in the IL-1β
and TNF-α networks at 72 hours.
IL-1β

TNF-α

Adamts16; Col11a1; Col15a1; Col25a1;
miR-29b- Col27a1; Col2a1; Col6a2; Col8a1;
Col9a1; Creb5; Dio2; Eln; Ibsp; Lif;
3p
Mstn; Mybl2; Pik3cb

Adam19; Adamts16; Adamts20;
Col11a1; Col15a1; Col19a1; Col1a1;
Col1a2; Col22a1; Col27a1; Col2a1;
Col3a1; Col5a1; Col8a1; Col9a1;
Creb5; Eln; Hif3a; Ibsp; Itga11; Mstn;
Pdgfb

Acvr1b; Adamts5; Atp1a2; Bmp2; Il6st;
miR-17-5p Itgb8; Jag1; Pdgfra; Ppara; Runx1;
Tnfrsf21; Tnfsf11

Adamts5; Bmp2; Bmp2k; Col4a4; Ereg;
Itgb7; Lif; Vegfa

Acvr1b; Adamts5; Atp1a2; Bmp2; Il6st;
miR-20aItgb8; Jag1; Pdgfra; Ppara; Runx1;
5p
Tnfrsf21; Tnfsf11

Adamts5; Bmp2; Bmp2k; Col4a4; Ereg;
Itgb7; Lif; Vegfa

*All interactions are listed, and interactions that have been experimentally validated are
bolded.

3.4.4 In vitro validation of miRNA-mRNA interactome targets

To probe specific miRNA-mRNA interactions and to determine the therapeutic potential
of hub miRNAs within the networks, miRNA mimics or inhibitors were delivered to monolayer
chondrocyte-like cells prior to challenge with inflammatory cytokines. The miR-29b-3p hub had
the most connections to inflammation and cartilage/OA related genes in both the IL-1β and TNFα networks, and RNA-sequencing analysis shows that miR-29b-3p expression increased over
time (Figure 3.13). miR-29b-3p mimics and inhibitors alone had no significant effect on the
overall inflammatory status of the cells in response to either cytokine. Expression levels of Ccl2
and Mmp13, markers of inflammation and matrix degradation in OA, were not significantly
decreased with miR-29b-3p mimic or inhibitor delivery 24 hours after inflammatory cytokines
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Figure 3.13 RNA-sequencing analysis expression of hub miRNAs miR-29b-3p, miR-17-5p,
and miR-20a-5p in response to inflammatory cytokines, 0.5 ng/mL IL-1β or 20 ng/mL TNFα. LFC, log2(FoldChange).

were given to cells, as compared to their respective controls (Figure 3.14A). Furthermore, miR29b-3p mimics and had no effect on the MMP activity levels at 24 and 48 hours in TNF-α
groups. Likewise, there were no significant differences in MMP activity levels after 24 hours in
IL-1β exposed cells; however, at 48 hours, miR-29b inhibitor resulted in significantly lower
MMP activity levels as compared to the inhibitor control, but this effect was not significant when
compared to the non-transfected control (Figure 3.14B).
In addition to the miRNA-29b-3p hub, network analysis revealed that miR-20a-5p and
miR-17-5p, which are miRNAs expressed from the miR-17~92 cluster, may also be controlling
the inflammatory response of tissue engineered cartilage to inflammation. RNA-sequencing
results show that both miR-20a-5p and miR-17-5p increase from 4 to 24 hours, but slightly
decrease from 24 to 72 hours in both IL-1β and TNF-α stimulated pellets (Figure 3.13). With the
addition of miRNA-20a & 17-5p mimics, there is a significant decrease in Mmp13 and Ccl2
expression at 24 hours after IL-1β and TNF-α delivery (Figure 3.15A). Additionally, there is a
significant decrease in MMP activity in culture media at both 24 and 48 hours when miRNA-20a
& 17-5p mimics are delivered to IL-1β and TNF-α stimulated pellets. The addition of miR-29b3p mimics further decreases MMP activity levels in cell culture supernatant at 24 hours in both
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IL-1β and TNF-α groups as compared to miRNA-20a & 17-5p mimics alone, while the addition
of miR-29b-3p inhibitor did not show significantly lower levels of MMP activity with either
cytokine or at any time point (Figure 3.15B).

A

B

Figure 3.14 In vitro evaluation of miR-29b-3p mimic and inhibitor delivery. miR-29b-3p
mimics (M) and inhibitors (I) were delivered and cells were challenged with 0.5 ng/mL IL-1β
or 20 ng/mL TNF-α to evaluate (A) Ccl2 and Mmp13 gene expression after 24 hours as
measured by qRT-PCR and (B) MMP activity in cell culture media after 24 and 48 hours
(n=4; mean±SEM). Fold changes were determined relative to NT (non-transfected) control
group. For each cytokine, groups with different letters are statistically significant (p<0.05):
n.s., not significant.
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Figure 3.15 In vitro evaluation of miR-17-5p and miR-20a-5p mimic and inhibitor delivery.
miR-17-5p and miR-20a-5p mimics (M) and inhibitors (I) were delivered in combination and
cells were challenged with 0.5 ng/mL IL-1β and 20 ng/mL TNF-α to evaluate (A) Ccl2 and
Mmp13 gene expression after 24 hours as measured by qRT-PCR and (B) MMP activity
levels in cell culture media, determined with and without the further addition of miR-29b-3p
mimics and inhibitors. (n=4; mean±SEM). Fold changes were determined relative to NT
(non-transfected) control group. For each cytokine, groups with different letters are
statistically significant (p<0.05): n.s., not significant.

3.5 Discussion
In this study, we quantified the transcriptomic changes that occur over time in tissue
engineered cartilage in response to inflammatory cytokines IL-1β and TNF-α. Integration of
mRNA and miRNA RNA-sequencing data sets in response to these cytokines revealed
regulatory networks, in which the mechanisms of action for previously studied and novel hub
miRNAs can be explored as well as their ability to modulate inflammation. Our results show the
presence of distinct as well as common miRNA signatures in response to these cytokines,
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resulting in complex changes in the miRNA-mRNA interactome over time. These findings
provide further data in support of the use of iPSCs-derived cartilage as a system for in vitro
disease modeling and have important implications for the development of new approaches to
target the chondrocyte inflammatory response.
Through RNA-sequencing analysis, we determined the temporal and dynamic response
of genes to specific inflammatory cytokines. There have been a number of previous studies
exploring the differentially expressed genes in OA tissues as compared to controls (Fisch et al.,
2018; Soul et al., 2018; Steinberg et al., 2017), and a few that explore the time course of OA
(Loeser et al., 2013; Löfgren et al., 2018; Svala et al., 2015). However, these studies are on the
scale of days-weeks, where previous studies have shown specific, dynamic patterns of gene
expression in response to inflammatory stimuli within hours (Hao & Baltimore, 2009). Here, we
found that different genes were up- and down-regulated at various time points, with genes
expressed at each time point exclusively and expressed across multiple time points (Figures 3.3A
and 3.3C). Over time, differentially expressed genes in response to either IL-1β and TNF-α were
found to be involved in similar inflammation and matrix degradation signaling pathways (Table
3.1 and 3.2). Furthermore, cluster analysis revealed the patterns of temporal expression of genes
in response to inflammatory cytokines (Figure 3.4). These findings provide a comprehensive
exploration of the transcriptomic changes of tissue-engineered cartilage, as well as time course of
these responses, both of which is important for guiding therapies to inhibit both chronic
inflammation and flares that occur within a diseased joint.
Similarly, we characterized the temporal response of miRNAs to IL-1β and TNF-α and
found that most of the differentially expressed miRNAs were up- and down-regulated at the 24
and 72 hour time points. There were a number of shared miRNAs, such as miR-155-3p and miR79

146a-5p, which have previously been implicated in inflammatory responses of various cells
(Kriegsmann et al., 2016; Soyocak et al., 2017; Taganov et al., 2006; Yamasaki et al., 2009), and
have significantly increased expression in response to both cytokines in these findings.
Interestingly, miR-155-5p and miR-222-3p were miRNAs that were significantly up-regulated at
4 hours. In bovine articular cartilage, miR-222-3p has been shown to have higher expression in
weight-bearing regions of articular cartilage condyles and therefore, is thought to play a role in
mechanotransduction (Dunn et al., 2009). Superficial zone cartilage shows a higher expression of
miR-222 compared to middle zone chondrocytes, and during dedifferentiation and subsequent
redifferentiation, expression of miR-222 increased and then decreased, respectively (Hong &
Reddi, 2013). Furthermore, in developing human cartilage, miR-222 was found to be more
highly expressed in hypertrophic compared to precursor chondrocytes (McAlinden et al., 2013).
These findings implicate a role for miR-222-3p in chondrogenesis. Our results suggest that this
miRNA is also rapidly responsive to inflammatory cytokines.
We also identified several miRNAs that showed unique responses to IL-1β or TNF-α. For
example, miR-210-5p expression was significantly decreased in response to TNF-α but not IL1β. Previous studies of animal models of OA have shown that delivery of miR-210 can reduce
inflammation in the joint space by inhibiting NF-κB (Dawei Zhang et al., 2015). Another
example is miR-140, which is highly expressed in articular cartilage and a critical regulator of
skeletal development and cartilage homeostasis (Miyaki et al., 2009; Nakamura et al., 2011).
Some studies, however, show that miR-140 is increased, while others show decreased expression
in OA cartilage (McAlinden & Im, 2018). In our study, miR-140-3p was the third most abundant
miRNA across all samples and was significantly decreased only in response to TNF-α at 72
hours. This finding could explain the confounding results for miR-140 in OA studies as this
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miRNA appears to be both stimulus- and time-dependent. miRNAs that have not been previously
implicated in healthy or diseased cartilage were also discovered through this analysis, such as
miR-341-5p and miR-665-3p which were significantly decreased with both inflammatory
cytokines, miR-154-3p which was significantly downregulated with IL-1β treatment only, and
miR-421-5p, miR-7678-3p, miR-6972-3p, and miR-147-3p which were TNF-α specific.
To obtain a more complete understanding of the specific molecular mediators and
networks regulating OA, studies are now using integrative -omics approaches (genomics,
transcriptomics, proteomics, metabolomics, lipidomics, and epigenomics) (Ratneswaran et al.,
2020). However, few studies have investigated the miRNA interactome by correlating miRNA
expression levels to protein or mRNA changes in human OA tissues (Coutinho De Almeida et
al., 2019; Iliopoulos et al., 2008). Here, we sought to provide an in-depth analysis of the specific
contributions of IL-1β and TNF-α, as well as determine the response of tissue engineered
cartilage to the inflammatory environment of an OA joint. Thus, we created networks of
miRNA-mRNA interactions which may be controlling the response to inflammatory cytokines
IL-1β and TNF-α (Figures 3.9 and 3.11) through integration of mRNA and miRNA sequencing
data. Using this approach, we were able to identify key miRNAs of interest, miR-29b-3p, miR17-5p, and miR-20a-5p. miR-29b has been reported to be increased in both joint tissues in a
murine model of OA and human OA cartilage tissues and negatively regulates Smad, NF-κB,
and canonical Wnt signaling pathways (Le et al., 2016). In this study, miR-29b-3p was
significantly increased in response to both IL-1β and TNF-α and has the most connections to
inflammation related genes in both validated networks (Figures 3.9 and 3.11). However, miR29b-3p mimics or inhibitors alone were not able to attenuate inflammation in cells (Figures
3.14).
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The other hub miRNAs identified in this study were miR-20a-5p and miR-17-5p, which
are members of the miR-17~92 cluster. The miR-17~92 family has been extensively studied as
an oncogene, however its role in other processes such as proliferation, development, and
differentiation have also been explored (Bai et al., 2019). While the role of this miRNA cluster in
OA has not been reported, miR-17 and miR-20a showed significantly increased expression in
hypertrophic chondrocytes as compared to precursor and differentiated chondrocytes in
developing human cartilage (McAlinden et al., 2013). Additionally, in humans with mutations in
MIR17HG (the gene encoding the miR-17~92 family), display features of Feingold syndrome,
including skeletal abnormalities (de Pontual et al., 2011) and mice with hemizygous deletion of
the miR-17~92 cluster replicate the features seen in humans. Furthermore, this cluster has
recently been implicated in the response of fibroblast-like synoviocytes, the resident cells of the
synovial membrane, to inflammation in rheumatoid arthritis (Philippe, Alsaleh, Bahram, et al.,
2013; Philippe, Alsaleh, Pichot, et al., 2013). Here, we found a novel role for the miR-17~92
cluster, specifically miR-17-5p and miR-20a-5p, in the ability to modulate the inflammatory
response of tissue engineered cartilage. We show that delivery of miR-20a-5p and miR-17-5p
mimics significantly decreases the MMP activity level, while also decreasing Mmp13 and Ccl2
expression levels in IL-1β and TNF-α treated cells (Figure 3.15A). Furthermore, the addition of
miR-29b-3p further decreased MMP activity levels, showing that targeting multiple hubs within
the networks can increase the efficacy of miRNA targeted therapies (Figure 3.15B). Connected
genes which may be direct targets and controlling this response are Adamts5, TGF-β signaling
pathway members (Bmp2, Acvr1b), and inflammation pathway related genes (Tnfsf11, Il6st,
Acvr1b, Tnfrsf21, Pdgfra, Lif, Vegfa).
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In comparison to a previously reported OA miRNA-mRNA interactome (Coutinho De
Almeida et al., 2019), hub miRNAs from this study were also significantly DE in lesioned
compared to preserved OA cartilage. Additionally, genes connected to miR-20a-5p and miR-175p, such as Adamts5, Bmp2, Vegfa, and Lif, and genes connected to miR-29b-3p, interestingly,
many collagen genes (Col2a1, Col6a2, Col8a1, Col9a1, Col11a1, Col15a1, Col25a1, and
Col27a1), were also DE in lesioned compared to preserved OA cartilage. However, this study
did not find strong inverse correlations for any of these interactions, which could be due to the
different experimental systems.
In summary, this study utilized an integrative approach to determine the miRNA-mRNA
interactome controlling the response of tissue-engineered cartilage to inflammatory cytokines.
The miRNA hubs identified through this analysis, miR-17-5p and miR-20a-5p, were further
validated by showing that delivery of mimics for these miRNAs significantly decreased
degradative enzyme production, as well as the expression of inflammation related genes.
Furthermore, we found that targeting multiple miRNAs further decreased inflammation in cells,
highlighting the importance of comprehensively assessing the entire miRNA interactome.
Importantly, several of the hub miRNAs and connected genes identified in this study are
consistent with those previously shown to be DE in human OA tissues, providing further support
for the use of this iPSC-based system as an in vitro model of human disease. This integrative
analysis allowed us to discover novel mediators and mechanisms of inflammation in tissueengineered cartilage and provides information to guide future studies seeking novel miRNA
targeted therapies for arthritic diseases.
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3.5 Conclusions
Cartilage degradation in osteoarthritis is mediated in part by the action of inflammatory
cytokines. The effect of these cytokines on the complete transcriptome of chondrocytes, or on the
miRNAs that interact with mRNAs to regulate gene expression, remain to be determined. Here
we used an in vitro model of engineered cartilage to determine and validate the temporal changes
in the mRNA-miRNA “interactome” in response to interleukin 1 or tumor necrosis factor alpha.
Our findings reveal distinct time-dependent mRNA and miRNA interaction patterns in response
to different cytokines and provide insights into the identification of novel targets for modulating
the inflammatory response as a therapeutic approach for preventing osteoarthritis or enhancing
the efficacy of engineered cartilage repair.
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Chapter 4: Conclusions and Future
Directions
Articular cartilage covers articulating bone surfaces in diarthrodial joints, providing a
near-frictionless and wear resistant surface for decades in healthy individuals. When articular
cartilage degenerates, it loses its abilities to bear loads, dissipate energy, and provide joint
lubrication, ultimately leading to osteoarthritis (OA). The development of tissue engineering
strategies for the regeneration of articular cartilage remains challenging due to the harsh
inflammatory environment of an injured or arthritic joint in which inflammatory cytokines
promote degradation of engineered tissues as well as native articular cartilage.
The work detailed in this dissertation established novel approaches for the protection of
tissue engineered cartilage from inflammation-driven degradation. First, an inflammationresponsive synthetic gene circuit was engineered towards the goal of developing an
autoregulated biologic system for application in tissue engineering and drug delivery in a range
of disease applications. It was hypothesized that tissue engineering, gene therapy, and synthetic
biology approaches could be combined to create a cartilaginous tissue that is capable of replacing
damaged tissue while delivering therapeutic drugs to a diseased joint in a time- and dosedependent manner. Second, a miRNA-mRNA interactome of tissue-engineered cartilage was
revealed towards to the goal of determining the effect of inflammatory cytokines on the
transcriptome of chondrocytes. It was hypothesized that integrative analysis of miRNA and
mRNA sequencing data would identify key mediators driving inflammatory responses of
chondrocytes in tissue engineered cartilage.
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In Chapter 2, we created an artificial gene circuit, based on a nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB)-responsive synthetic promoter, for controlled, cellbased delivery of biologic drugs. Delivery of this lentiviral vector to murine iPSCs (miPSCs)
resulted in self-regulating cells that were capable of forming engineered cartilage for the
replacement of diseased tissue and mitigating the inflammatory effects of IL-1α. Furthermore,
biomaterial-mediated delivery of this vector provided efficient transduction and effectively
attenuated inflammatory signaling. To our knowledge, this is the first report of a lentiviral,
synthetic system in iPSCs for cartilage tissue engineering. By leveraging the flexibility of
lentiviral transduction in tissue engineering applications, we demonstrated proof-of-concept of a
targeted delivery method allowing for spatial control of therapy via biomaterial-mediated
transduction. NF-κB is a critical mediator of inflammatory responses in many cell types and
lentiviral vectors can stably integrate into the genome of dividing and non-dividing cells. Thus,
the customization of this system could be broadly applied in future studies where precise antiinflammatory delivery is desired for cells in monolayer, in engineered tissue replacements, or in
a spatially controller manner through scaffold-mediated delivery.
To more completely understand the specific molecular mediators and networks regulating
OA, Chapter 3 describes a miRNA-mRNA interactome of tissue engineered cartilage in response
to inflammatory cytokines. Through RNA-sequencing analysis of the miRNA and mRNA
expression changes over time in response to IL-1β and TNF-α, we comprehensively analyzed of
the transcriptomic changes, as well as the time course of these responses. Both of these factors
are important for guiding therapies to inhibit both chronic inflammation and flares that occur
within a diseased joint. Furthermore, by studying the effects of IL-1β and TNF-α, the specific
miRNA mediators of these cytokines were determined. Through integration of miRNA and
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mRNA sequencing data sets, we created networks of miRNA-mRNA interactions which may be
controlling the response to inflammatory cytokines. Using this approach, we identified key
miRNAs, specifically miR-17-5p and miR-20a-5p, and showed that delivery of mimics for these
miRNAs attenuated degradative enzyme production and the expression of inflammation related
genes. Importantly, this work illustrates a novel role for the miR-17~92 cluster’s ability to
modulate the inflammatory response of tissue engineered cartilage and the potential mechanisms
of action.
This study provides an important advance in the understanding of the role of miRNAs in
cartilage, and visualization of the networks on a web application provides an interactive resource
for those researching in this field. However, much work remains to fully elucidate the
mechanisms by which miRNAs regulate molecular processes. Future studies modulating other
miRNAs, such as those in the network or those identified to be IL-1β or TNF-α specific, could
further reduce the inflammatory signaling in cells stimulated with cytokines. Additionally,
delivery of miRNA mimics or inhibitors to tissue engineered cartilage would further demonstrate
their therapeutic potential.
Furthermore, synthetic biology as a field provides a toolkit to build more complex and
specialized systems upon these findings. The components of the synthetic circuit developed in
Chapter 2 could be altered for fine-tuning expression levels or specificity of the promoter or for
production of a different transgene. miRNAs provide a potentially powerful set of regulatory
elements that could be used to control synthetic systems. Incorporation of the miRNAs from
Chapter 3 that have unique expression profiles in response IL-1β and TNF-α into gene circuits
could provide more precise and controlled therapeutic delivery systems.
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Overall, the data presented in this dissertation demonstrate alternative strategies by which
therapies can be discovered and delivered to OA joints. These findings describe ways to prevent
OA or enhance the efficacy of engineered cartilage repair, and also further our understanding of
disease processes and describe molecules, components, and methods that can be applied to tissue
engineering and drug delivery in a range of disease applications.
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Appendix Table 1 Enriched pathways of genes within each cluster in response to IL-1β.
Pathway

P-value Genes
Cluster 1

ECM-receptor
interaction
TNF signaling
pathway

-12

Sdc4; Lamb3; Gp1bb; Lama3; Tnc; Lamc2; Hmmr; Thbs2;
Thbs1; Gp5; Col2a1; Reln; Sv2c; Col4a1; Col6a2; Chad; Col9a1;
Col9a3; Col9a2; Cd44

-10

Edn1; Ccl12; Csf2; Ccl20; Lif; Pik3cb; Nod2; Ptgs2; Tnf; Sele;
Cxcl2; Nfkb1; Cx3cl1; Icam1; Cxcl10; Creb3l2; Ccl2; Junb;
Map3k5; Creb5

1.11x10

2.66x10

Pkn3; Lama3; Pdgfb; Tnc; Il6ra; Lamc2; Pik3cb; Fgf1; Thbs2;
PI3K-Akt
Areg; Fgf2; Thbs1; Pik3r5; Reln; Erbb4; Creb3l2; Chad; Fgf21;
1.48x10-8
Lamb3; Igf2; Nfkb1; Ereg; Col2a1; Col4a1; Col6a2; Fgf18;
signaling pathway
Col9a1; Bcl2; Gnb3; Col9a3; Kras; Col9a2; Fgfr3; Creb5
Fluid shear stress
Edn1; Ccl12; Sdc4; Cav1; Pdgfb; Calml3; Plat; Pik3cb; Tnf;
and
2.95x10-8 Prkcz; Sele; Nfkb1; Klf2; Actg1; Icam1; Nppc; Trpv4; Bcl2; Ccl2;
atherosclerosis
Map3k5
Col17a1; Col15a1; Col27a1; Kcne3; Eln; Col11a1; Col11a2;
Protein digestion
1.53x10-7 Slc1a5; Col2a1; Slc7a8; Col4a1; Col6a2; Col9a1; Col9a3;
and absorption
Col9a2
Cluster 2
Cytokine-cytokine
Gdf10; Il33; Bmp2; Mstn; Il1r1; Tnfsf10; Tnfsf8; Osmr; Prlr;
receptor
1.03x10-3
Il13ra1; Bmp15
interaction
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NOD-like
receptor signaling 3.96x10-3 Gsdmd; Gbp5; Oas3; Casp4; Tnfaip3; Gbp2; Nfkbib; Gbp3
pathway
Influenza A

4.85x10-3 Socs3; H2-dmb2; Il33; Rsad2; Oas3; Tnfsf10; Nfkbib

Notch signaling
2.24x10-2 Lfng; Rbpjl; Notch4
pathway
Epstein-Barr virus
2.35x10-2 Rbpjl; H2-dmb2; Oas3; Tnfaip3; H2-q10; Tlr2; Nfkbib
infection
Cluster 3
Drug Metabolism 4.00x10-3 Ces2e; Gsto1; Gstp2; Gstp1; Aox1; Upb1; Xdh
IL-17 Signaling
5.35x10-3 Ccl7; Traf5; Cxcl1; Traf2; Ikbke; Cxcl5
Pathway
Glycosphingolipid
7.89x10-3 Fut9; St8sia1; A4galt; Ggta1
Biosynthesis
TNF Signaling
Pathway

1.31x10-2 Jag1; Irf1; Ccl5; Traf5; Cxcl1; Traf2

Cytokine-cytokine
Ccr1; Il21; Cxcl9; Acvr1c; Ccl7; Ifngr2; Ccl5; Cxcl1; Il13ra2;
Receptor
1.45x10-2
Eda2r; Cxcl5
Interaction
Cluster 4
Arrhythmogenic
right ventricular
4.78x10-5 Dsp; Ryr2; Cacng8; Itgb3; Itga10; Tcf7; Pkp2; Itga7; Sgcg; Itga9
cardiomyopathy
(ARVC)
Glutathione
metabolism

1.03x10-4 Gclc; Gsta4; Gsta3; Gss; G6pdx; Gsr; Gsta1; Pgd; Gclm

Cytokine-cytokine
Il11; Csf3; Csf1; Gdf15; Il4ra; Il1f9; Cxcl3; Ngf; Il2rg; Cxcl14;
-4
receptor
4.50x10 Il17rb; Bmp6; Bmp3; Il1rl1; Il6; Il18rap; Il7; Tnfsf4; Cd27;
interaction
Il12rb1
Rheumatoid
arthritis

8.19x10-4

Mmp1b; Il11; Il6; Csf1; Cd80; Cd28; Atp6v0a4; Atp6v0e2;
Atp6v1c2
108

Hematopoietic
cell lineage

1.83x10-3 Il11; Cd24a; Csf3; Il6; Csf1; Il7; Itgb3; Il4ra; Cd14
Cluster 5

Metabolism of
Cbr2; Gstm2; Ugt2b34; Ugt1a1; Gstt4; Mgst1; Mgst2; Gstt1;
-11
xenobiotics by 2.52x10 Ugt1a6a; Ugt1a6b; Ugt1a7c; Hsd11b1; Adh1; Ugt1a5; Cyp1b1;
cytochrome P450
Ugt1a2; Cyp2f2; Gstm7; Gstm6

Pathways in
cancer

Lamc3; Il23r; Calml4; Gli2; Fgf7; Il12b; Rac3; Pim2; Ifnar2;
Pdgfra; Prkcb; Hgf; Mmp2; Wnt16; Mmp9; Pgf; Runx1; Plcb4;
Il3ra; Pparg; Il6st; Birc3; Camk2b; Epas1; Lama1; Gstt4; Mgst1;
9.36x10-10 Mgst2; Gstt1; Lpar3; Csf2rb; Adcy1; Lpar4; Rasgrp2; Kng2;
Egfr; Kng1; Adcy5; Gng2; Abl1; Egln1; Gstm2; Fzd2; Fzd4;
Tgfb3; Fzd8; Vegfd; Lamb1; Igf1; Nfkbia; Cxcl12; Kitl; Fas;
Gstm7; Gstm6; Fgf10

Gstm2; Ugt2b34; Maob; Ugt1a1; Gstt4; Mgst1; Mgst2; Fmo1;
Drug metabolism 1.70x10-8 Gstt1; Nme4; Ugt1a6a; Ugt1a7c; Ugt1a6b; Adh1; Nat1; Ces2g;
Ces1f; Ugt1a5; Ugt1a2; Gstm7; Gstm6
Chemical
carcinogenesis

Gstm2; Ugt2b34; Ugt1a1; Gstt4; Mgst1; Mgst2; Gstt1; Ugt1a6a;
9.54x10-8 Ugt1a6b; Ugt1a7c; Hsd11b1; Adh1; Nat1; Ugt1a5; Cyp1b1;
Ugt1a2; Gstm7; Gstm6

Acvrl1; Amhr2; Il23r; Csf2rb; Cxcl13; Acvr1b; Cxcl15; Ccl9;
Cytokine-cytokine
Ccl8; Ccl6; Ccl27a; Tnfsf11; Il12b; Ccr10; Ifnar2; Tnfsf14;
receptor
1.43x10-6
Tnfsf15; Il10rb; Tgfb3; Il34; Tnfrsf9; Lifr; Inhbb; Il17re; Il17ra;
interaction
Edar; Cxcl12; Il3ra; Tnfsf9; Fas; Il6st; Tnfrsf21
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Appendix Table 2 Enriched pathways of genes within each cluster in response to TNF-α.
Pathway

P-value Genes
Cluster 1

TNF signaling
pathway

8.39x10-4 Mapk10; Ccl12; Vcam1; Irf1; Ccl2; Fas; Birc3

Cytokine-cytokine
Il33; Ccl12; Bmp2; Acvr1c; Fas; Ccl2; Il17re; Tnfrsf11a; Gdf6;
receptor
2.55x10-3
Prlr; Il12rb2
interaction
Malaria

4.62x10-3 Ccl12; Vcam1; Hgf; Ccl2

Hippo signaling
6.66x10-3 Wnt10a; Bmp2; Lef1; Gdf6; Wnt16; Nkd1; Actg1
pathway
Wnt signaling
pathway

6.89x10-3 Mapk10; Wnt10a; Lef1; Rspo3; Wnt16; Lgr5; Nkd1
Cluster 2

Influenza A

1.14x10-6

H2-eb1; Rsad2; Ddx58; Pik3cd; Oas1a; H2-aa; Oas1g; Ifih1;
Oas2; Oas3; Tnfsf10; Irf7; Hspa1b

Epstein-Barr virus
Entpd1; H2-eb1; Syk; Ddx58; H2-q6; Oas1a; Pik3cd; Isg15; H23.30x10-5
infection
aa; Oas1g; Oas2; Oas3; Irf7
NOD-like
Gsdmd; Panx1; Gbp7; Aim2; Ifi204; Oas2; Oas3; Irf7; Oas1a;
receptor signaling 4.91x10-5
Tmem173; Oas1g; Gbp3
pathway
Measles

5.03x10-5

Ifih1; Ddx58; Oas2; Oas3; Irf7; Pik3cd; Oas1a; Il2rg; Hspa1b;
Oas1g

Cytokine-cytokine
Cxcl9; Csf1; Ngf; Tnfrsf1b; Il2rg; Cxcl14; Cxcl15; Il1rl1; Ccl9;
receptor
1.03x10-4
Il1rl2; Il18rap; Tnfsf4; Tnfsf10; Il12rb1
interaction
Cluster 3
TNF signaling
pathway

1.87x10

-12

Edn1; Cebpb; Csf2; Ccl20; Lif; Tnfaip3; Cxcl1; Nod2; Ptgs2; Tnf;
Sele; Cxcl2; Nfkb1; Cx3cl1; Icam1; Nfkbia; Cxcl10; Il6; Creb3l3;
Junb; Creb5
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Cntfr; Il1rn; Cd40; Csf3; Csf2; Il20rb; Cxcr4; Cxcl1; Cxcr6; Tnf;
Cytokine-cytokine
Cxcl2; Cx3cl1; Cxcl5; Bmp15; Tnfsf11; Il11; Tnfsf15; Ccl20;
receptor
2.45x10-11
Tnfrsf19; Lif; Bmp8a; Il19; Gdf5; Bmp4; Cxcl10; Il6; Il23a; Il7;
interaction
Lep; Tnfsf9; Inha; Il17a
Col15a1; Col27a1; Kcne3; Eln; Col11a1; Col22a1; Col12a1;
Protein digestion
-11 Col11a2; Col1a1; Col3a1; Col2a1; Col1a2; Slc7a8; Col5a1;
3.20x10
and absorption
Col9a1; Col9a3; Col9a2; Kcnn4
IL-17 signaling
pathway

2.93x10-9

Csf3; Cebpb; Csf2; Ccl20; Tnfaip3; Cxcl1; Ptgs2; Cxcl2; Tnf;
Cxcl5; Nfkb1; Nfkbia; Fosl1; Cxcl10; Il6; Il17a

ECM-receptor
interaction

6.19x10-9

Lama2; Tnc; Thbs2; Thbs4; Col1a1; Col2a1; Reln; Col1a2; Sv2b;
Chad; Itga11; Col9a1; Col9a3; Col9a2; Cd44
Cluster 4

Metabolism of
Gstm1; Gsto1; Gstt4; Mgst1; Mgst2; Ugt1a6a; Ugt1a6b;
xenobiotics by 2.62x10-10
Ugt1a7c; Aldh1a3; Aldh3a1; Gsta4; Gsta3; Ugt1a5; Cyp1b1
cytochrome P450
Chemical
carcinogenesis

3.27x10-8

Drug metabolism 5.84x10-8
IL-17 signaling
pathway
Pathways in
cancer

1.68x10-7

Gstm1; Gsto1; Gstt4; Mgst1; Mgst2; Ugt1a6a; Ugt1a6b;
Ugt1a7c; Aldh1a3; Aldh3a1; Gsta4; Gsta3; Ugt1a5; Cyp1b1
Gstm1; Gsto1; Gstt4; Mgst1; Mgst2; Ugt1a6a; Ugt1a7c;
Ugt1a6b; Aldh3a1; Aldh1a3; Ces2e; Gsta4; Gsta3; Ugt1a5; Xdh
Mmp1b; Mmp3; Cxcl3; Mmp9; Mapk13; Mapk11; Mmp13; Traf4;
Ccl7; Traf5; Ikbkg; Ikbke; S100a8

Mmp1b; Csf1r; Notch3; Il23r; Gstt4; Mgst1; Mgst2; Adcy1;
Calml4; Lpar4; Fgf7; Casp7; Fgf9; Pmaip1; Ikbkg; Bid; Gstm1;
1.02x10-6
Fzd4; Gsto1; Gadd45a; Ifngr2; Fzd6; Vegfc; Traf1; Mmp9;
Traf4; Gsta4; Gsta3; Col4a4; Traf5; Mdm2; Pparg
Cluster 5

Proximal tubule
bicarbonate
5.81x10-5 Fxyd2; Atp1a2; Atp1b1; Slc38a3
reclamation
Mineral
absorption

7.01x10-5 Fxyd2; Trf; Atp1a2; Mt2; Atp1b1
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Cytokine-cytokine
Gdf10; Il15ra; Bmp3; Tnfsf14; Mstn; Amhr2; Il15; Ccl5; Cxcl13;
receptor
1.58x10-4
Ccr3; Il27ra
interaction
Carbohydrate
digestion and
absorption

8.34x10-4 Fxyd2; Atp1a2; Amy1; Atp1b1

Intestinal immune
network for IgA 8.34x10-4 H2-dmb2; Il15ra; Il15; Madcam1
production
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Appendix Table 3 Enriched pathways of genes in response to IL-1β at each time point.
Pathway

P-value Genes
4 hour

TNF signaling
pathway

Cebpb; Csf2; Csf1; Tnfaip3; Cxcl1; Nod2; Cxcl3; Ptgs2; Tnf;
Cxcl2; Cx3cl1; Icam1; Socs3; Ccl5; Ccl2; Junb; Edn1; Vcam1;
6.37x10-23
Ccl20; Mmp3; Lif; Ifi47; Traf1; Sele; Mmp9; Nfkb1; Nfkbia;
Cxcl10; Mapk11; Il6; Irf1; Bcl3; Fas; Creb5; Birc3

Il21; Il1rn; Cd40; Csf3; Cxcl9; Csf2; Mstn; Csf1; Il1f9; Cxcl1;
Cxcl3; Tnf; Cxcl2; Cx3cl1; Cxcl5; Cxcl16; Il18rap; Tnfsf10;
Cytokine-cytokine
Tnfsf11; Il12b; Tnfrsf8; Il13ra2; Il19; Il17re; Osmr; Il4ra; Il20rb;
receptor
4.90x10-19
Il2rg; Acvr1b; Il1rl1; Il1rl2; Acvr1c; Ccl7; Ccl5; Ccl2; Ccr10;
interaction
Tslp; Tnfsf14; Tnfsf15; Ccl20; Tgfb3; Tnfrsf9; Lif; Cxcl10; Bmp2;
Il6; Il7; Tnfsf4; Fas; Tnfsf8
IL-17 signaling
pathway

Mmp1b; Csf3; Cebpb; Csf2; Tnfaip3; Cxcl1; Cxcl3; Ptgs2; Cxcl2;
4.45E-16 Tnf; Cxcl5; Ccl7; Ccl2; Ikbke; Ccl20; Mmp3; Il17re; Mmp9;
Nfkb1; Nfkbia; Fosl1; Mapk11; Cxcl10; Il6; Mmp13; S100a8

NOD-like
Tnfaip3; Cxcl1; Nod2; Cxcl3; Tnf; Cxcl2; Ccl5; Casp4; Nlrp3;
-7
receptor signaling 1.02x10 Ccl2; Gbp2; Ikbke; Camp; Gbp3; Gsdmd; Gbp5; Ifi207; Ifi204;
pathway
Ripk2; Cybb; Nfkb1; Nfkbia; Mapk11; Il6; Aim2; Birc3
Rheumatoid
arthritis

1.14x10-7

Mmp1b; H2-eb1; Csf2; Csf1; Tgfb3; Ccl20; Mmp3; Tnf; Cxcl5;
Icam1; Il6; Ccl5; Cd28; Tnfsf11; Ccl2; Tlr2

NF-kappa B
Cd40; Vcam1; Tnfsf14; Tnfaip3; Traf1; Ptgs2; Tnf; Cxcl2; Nfkb1;
3.49x10-7
signaling pathway
Icam1; Nfkb2; Relb; Nfkbia; Plau; Tnfsf11; Card14; Birc3
12 hour
Il21; Il1rn; Csf3; Cxcl9; Mstn; Csf1; Amhr2; Il1f9; Cxcl1; Cxcl3;
Tnf; Cxcl14; Cxcl2; Eda2r; Cx3cl1; Cxcl5; Bmp15; Il18rap;
Cytokine-cytokine
Ccl27a; Tnfsf11; Il13ra2; Il11; Ngf; Prlr; Ccl12; Il4ra; Csf2rb;
receptor
1.06x10-15
Il2rg; Il1rl1; Il1rl2; Ccl9; Ccl7; Ccl5; Ccl2; Il12rb1; Ccr1;
interaction
Gdf10; Il33; Tnfsf15; Ccl20; Gdf15; Tnfrsf9; Lif; Bmp2; Il6; Il7;
Tnfsf4; Tnfsf9; Cd27; Fas; Tnfsf8; Il17a
TNF signaling
pathway

Cebpb; Ccl12; Csf1; Tnfaip3; Cxcl1; Nod2; Cxcl3; Ptgs2; Tnf;
5.77x10-13 Cxcl2; Cx3cl1; Icam1; Ccl5; Ccl2; Mlkl; Ccl20; Mmp3; Lif;
Traf1; Sele; Mmp9; Nfkbia; Mapk11; Il6; Irf1; Fas; Creb5; Birc3
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Mmp1b; Csf3; Cebpb; Ccl12; Ccl20; Mmp3; Tnfaip3; Cxcl1;
IL-17 signaling
7.89x10-11 Cxcl3; Ptgs2; Cxcl2; Tnf; Mmp9; Cxcl5; Nfkbia; Fosl1; Mapk11;
pathway
Il6; Mmp13; Ccl7; Ccl2; S100a8; Il17a

Pathways in
cancer

Mmp1b; Calml4; Gli1; Fgf7; Bdkrb1; Prkcb; Gsto1; Dcc; Dapk2;
Mitf; Traf1; Wnt16; Mmp9; Agtr1a; Rarb; Met; Birc3; Ptger4;
Camk2b; Gstp2; Epas1; Gstp1; Notch4; Tcf7; Pdgfb; Il4ra;
4.39x10-9 Pdgfa; Lpar3; Csf2rb; Lpar4; Ptgs2; Il2rg; Hmox1; Pmaip1; Bid;
Il12rb1; Egln1; Arnt2; Nqo1; Wnt10a; Egln3; Nos2; Wnt7b;
Txnrd1; Fzd8; Vegfc; Igf1; Nfkb2; Vegfa; Nfkbia; Bmp2; Il6;
Gsta4; Gsta3; Il7; Gsta1; Mdm2; Fas; Gstm7; Fgfr3

Rheumatoid
arthritis

Mmp1b; Il11; Ccl12; Csf1; Ccl20; Cd80; Mmp3; Tnf; Cxcl5;
2.50x10-8 Icam1; Vegfa; H2-dmb2; Il6; Ccl5; Ctla4; Tnfsf11; Ccl2; Tlr2;
Il17a
24 hour

TNF signaling
pathway

Cebpb; Csf1; Tnfaip3; Cxcl1; Nod2; Cxcl3; Tnf; Cxcl2; Cx3cl1;
Icam1; Socs3; Ccl5; Creb3l2; Ccl2; Junb; Ccl20; Mmp3; Lif;
2.81x10-16
Ifi47; Traf2; Traf1; Sele; Mmp9; Nfkbia; Cxcl10; Mapk11; Il6;
Irf1; Bcl3; Traf5; Fas; Creb5; Birc3

Mmp1b; Csf3; Cebpb; Traf3ip2; Tnfaip3; Cxcl1; Cxcl3; Cxcl2;
IL-17 signaling
Tnf; Cxcl5; Ccl7; Ccl2; Ikbke; Ccl20; Mmp3; Traf2; Mmp9;
3.01x10-15
Il17rb; Nfkbia; Fosl1; Mapk11; Cxcl10; Il6; Mmp13; Traf5;
pathway
Lcn2; Il17d; S100a8; Il17a
Il1rn; Cd40; Csf3; Cxcl9; Mstn; Csf1; Il23r; Il1f9; Cxcl1; Cxcl3;
Tnf; Cxcl14; Cxcl2; Cx3cl1; Cxcl15; Cxcl5; Bmp15; Il18rap;
Cytokine-cytokine
Tnfsf11; Il12b; Il13ra2; Ifngr2; Il19; Osmr; Prlr; Il17rb; Edar;
receptor
8.17x10-15
Il6st; Tnfrsf21; Il4ra; Il2rg; Acvr1b; Il1rl1; Il1rl2; Ccl9; Ccl7;
interaction
Ccl5; Ccl2; Gdf10; Il33; Tnfsf15; Ccl20; Tnfrsf9; Lif; Cxcl10;
Bmp2; Il6; Cxcl12; Cd27; Fas; Tnfsf8; Il17d; Il17a

Pathways in
cancer

Mmp1b; Lamc3; Il23r; Calml3; Lamc2; Calml4; Fgf2; Gli2;
Fgf7; Ednrb; Il12b; Rac3; Bdkrb1; Pim2; Gsto1; Dapk2; Ifngr2;
Traf2; Traf1; Mmp9; Runx1; Traf5; Il6st; Met; Birc3; Ptger4;
Camk2b; Epas1; Lama1; Ptger2; Il4ra; Mgst1; Pdgfa; Mgst2;
7.02x10-9
Gstt1; Lpar3; Adcy1; Lpar4; Il2rg; Rasgrp2; Gng2; Wnt11; Bid;
Fgf21; Fzd1; Arnt2; Egln3; Fzd2; Nos2; Fzd4; Fzd9; Vegfc;
Lamb1; Nfkb2; Nfkbia; Bmp2; Il6; Cxcl12; Gsta4; Gsta3; Fgf18;
Fas; Fgfr3

114

Rheumatoid
arthritis

Mmp1b; Csf1; Ccl20; Cd80; Itgb2; Mmp3; Tnf; Cxcl5; Icam1;
1.75x10-8 H2-dmb2; Il6; Cxcl12; Ccl5; Cd28; Ctla4; Tnfsf11; Ccl2; Tlr2;
Atp6v1c2; Il17a
72 hour

Acvrl1; Il21; Il1rn; Cd40; Csf3; Cxcl9; Mstn; Il23r; Cxcl1;
Tnfrsf13c; Cxcl13; Cxcl3; Cxcl14; Cxcl2; Cx3cl1; Cxcl15; Cxcl5;
Bmp15; Il18rap; Tnfsf11; Il12b; Il13ra2; Il13ra1; Ifnar2; Il11;
Il1r1; Il19; Lifr; Osmr; Ngf; Il17rb; Il17ra; Edar; Il3ra; Il6st;
Cytokine-cytokine
receptor
2.21x10-16 Tnfrsf21; Il4ra; Il20rb; Il6ra; Tnfrsf11b; Il2rg; Acvr1b; Il1rl2;
Ccl9; Ccl8; Ccl7; Ccl6; Ccl5; Ccl2; Il12rb1; Gdf10; Il33;
interaction
Tnfsf14; Tnfsf15; Ccl20; Il10rb; Gdf15; Il34; Tnfrsf9; Lif; Inhbb;
Gdf5; Bmp6; Inhbe; Cxcl10; Bmp3; Bmp2; Il6; Cxcl12; Cd27;
Fas; Tnfsf8; Il17d
ECM-receptor
interaction

Lamc3; Lama1; Itgb3; Lama3; Lamc2; Hmmr; Thbs2; Thbs1;
Comp; Reln; Sv2c; Ibsp; Chad; Itgb8; Lamb3; Gp1bb; Itga1;
7.86x10-12
Lamb1; Npnt; Col2a1; Col4a1; Col6a2; Itga10; Itga8; Col9a1;
Itga7; Sdc1; Col9a3; Col9a2; Cd44

Pathways in
cancer

Mmp1b; Lamc3; Il23r; Calml3; Lamc2; Pik3cb; Fgf1; Fgf2;
Fgf7; Ednrb; Il12b; Rac3; Bdkrb1; Pim2; Il13ra1; Ifnar2;
Pdgfra; Prkcb; Dapk2; Hgf; Mmp2; Traf2; Mmp9; Pgf; Runx1;
Plcb4; Col4a1; Il3ra; Pparg; Il6st; Birc3; Ptger4; Epas1; Lama1;
Gstt4; Lama3; Il4ra; Mgst1; Mgst2; Tgfa; Il6ra; Gstt1; Lpar3;
5.42x10-9
Adcy1; Lpar4; Adcy8; Il2rg; Rasgrp2; Kng2; Egfr; Kng1; Adcy5;
Rasgrp3; Gng2; Wnt11; Abl1; Hes1; Il12rb1; Fgf21; Fzd1;
Gstm2; Jag1; Jup; Lamb3; Nos2; Fzd4; Fzd6; Fzd9; Igf2; Vegfc;
Vegfd; Lamb1; Igf1; Esr2; Nfkb2; Nfkbia; Bmp2; Il6; Cxcl12;
Kitl; Gsta3; Fgf18; Bcl2; Fas; Kras; Gstm7; Fgfr3; Gstm6; Fgf10

IL-17 signaling
pathway

Mmp1b; Csf3; Cebpb; Traf3ip2; Tnfaip3; Cxcl1; Cxcl3; Cxcl2;
Cxcl5; Ccl7; Ccl2; Ikbke; Ccl20; Mmp3; Traf2; Mmp9; Il17rb;
1.26x10-8
Il17ra; Nfkbia; Fosl1; Mapk11; Cxcl10; Il6; Mmp13; Lcn2; Il17d;
S100a8

Csf3; Lamc3; Itgb3; Lamc2; Pik3cb; Fgf1; Fgf2; Comp; Gys1;
Fgf7; Ibsp; Itgb8; Ifnar2; Pdgfra; Hgf; Itga1; Osmr; Ngf; Pgf;
Ereg; Col2a1; Col4a1; Col6a2; Il3ra; Itga8; Itga7; Sgk3; Tlr2;
PI3K-Akt
-8 Creb5; Pkn3; Lama1; Lama3; Il4ra; Tgfa; Lpar3; Il6ra; Lpar4;
4.67x10
signaling pathway
Il2rg; Thbs2; Thbs1; Egfr; Reln; Gng2; Erbb4; Chad; Fgf21;
Ntrk2; Lamb3; Igf2; Vegfc; Vegfd; Lamb1; Igf1; Il6; Kitl; Itga10;
Fgf18; Col9a1; Bcl2; Col9a3; Kras; Col9a2; Fgfr3; Fgf10
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TNF signaling
pathway

Cebpb; Tnfaip3; Cxcl1; Pik3cb; Nod2; Cxcl3; Cxcl2; Cx3cl1;
Socs3; Ccl5; Ccl2; Junb; Map3k5; Vcam1; Jag1; Ccl20; Mmp3;
6.79x10-8
Lif; Ifi47; Traf2; Mmp9; Nfkbia; Cxcl10; Mapk11; Il6; Bcl3; Fas;
Creb5; Birc3

Cell adhesion
molecules
(CAMs)

Cd274; H2-t23; Cd40; Cntnap1; H2-t22; Nlgn1; Nrxn1; H2-q6;
H2-k1; Itgb2; H2-q7; H2-q4; Vsir; H2-dmb2; Ctla4; Itgb8;
8.61x10-8 Madcam1; Jam2; Ntng1; Ntng2; Cadm3; H2-eb1; Vcam1; Icosl;
L1cam; H2-aa; Selp; Cldn11; Cldn10; Vcan; Cd6; Cldn7; Cntn1;
Cd28; Itga8; Sdc1; Siglec1; H2-q10

Kcnk5; Col17a1; Col15a1; Kcne3; Col14a1; Eln; Col11a1;
Col11a2; Atp1a3; Atp1a2; Slc1a5; Slc8a1; Col10a1; Col27a1;
Protein digestion
1.80x10-7
Mme; Slc8a3; Col2a1; Slc7a8; Col4a1; Col6a2; Col5a3; Fxyd2;
and absorption
Col9a1; Col9a3; Col9a2
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Appendix Table 4 Enriched pathways of genes in response to TNF-α at each time point.
Pathway
P-value Genes
4 hour
TNF signaling
pathway

Cebpb; Ccl12; Csf2; Csf1; Tnfaip3; Pik3cd; Cxcl1; Nod2; Cxcl3;
Ptgs2; Tnf; Cxcl2; Cx3cl1; Icam1; Ccl5; Ccl2; Edn1; Vcam1;
1.73x10-27
Mlkl; Il15; Ccl20; Mmp3; Lif; Ifi47; Traf1; Sele; Mmp9; Nfkb1;
Nfkbia; Mapk10; Cxcl10; Mapk11; Il6; Irf1; Fas; Birc3

Il1rn; Cd40; Csf3; Cxcl9; Csf2; Csf1; Il1f9; Cxcl1; Cxcl3; Tnf;
Cxcl2; Cx3cl1; Cxcl5; Cxcl16; Il18rap; Tnfsf11; Il13ra2; Il15ra;
Cytokine-cytokine
Il15; Tnfrsf19; Il23a; Csf1r; Ccl12; Il20rb; Cxcr4; Cxcr6;
receptor
1.44x10-22
Tnfrsf11a; Il2rg; Il1rl1; Il1rl2; Ccl9; Ccl7; Ccl5; Ccl2; Il12rb2;
interaction
Tslp; Tnfsf14; Tnfsf15; Ccl20; Il10rb; Lif; Cxcl10; Bmp2; Il6; Il7;
Tnfsf4; Lep; Fas; Il17a
Mmp1b; Csf3; Cebpb; Ccl12; Csf2; Tnfaip3; Cxcl1; Cxcl3; Ptgs2;
IL-17 signaling
1.59x10-18 Cxcl2; Tnf; Cxcl5; Ccl7; Ccl2; Ccl20; Mmp3; Mmp9; Nfkb1;
pathway
Nfkbia; Mapk10; Fosl1; Mapk11; Cxcl10; Il6; Mmp13; Il17a
Rheumatoid
arthritis

6.64x10-12

Mmp1b; Ccl12; Csf2; Csf1; Il15; Ccl20; Mmp3; Tnfrsf11a; Tnf;
H2-aa; Cxcl5; Icam1; Il6; Il23a; Ccl5; Tnfsf11; Ccl2; Tlr2; Il17a

Cd40; Vcam1; Tnfsf14; Syk; Tnfaip3; Tnfrsf11a; Traf1; Ptgs2;
NF-kappa B
-10 Tnf; Cxcl2; Nfkb1; Malt1; Icam1; Nfkb2; Relb; Nfkbia; Plau;
2.41x10
signaling pathway
Tnfsf11; Birc3
12 hour
TNF signaling
pathway

Ccl12; Csf1; Tnfaip3; Pik3cd; Cxcl1; Nod2; Cxcl3; Ptgs2; Tnf;
Cxcl2; Cx3cl1; Icam1; Ccl5; Ccl2; Edn1; Vcam1; Mlkl; Ccl20;
9.65x10-20
Mmp3; Lif; Ifi47; Traf1; Sele; Mmp9; Nfkbia; Cxcl10; Mapk11;
Il6; Irf1; Traf5; Fas; Creb5; Birc3

Ccl12; Csf3; Cxcl9; Csf1; Amhr2; Il1f9; Cxcr4; Cxcl1; Cxcl3;
Il2rg; Tnf; Cxcl2; Cx3cl1; Cxcl15; Cxcl5; Cxcl16; Il1rl1; Il1rl2;
Cytokine-cytokine
Ccl9; Il18rap; Acvr1c; Ccl7; Ccl5; Tnfsf10; Ccl2; Il13ra2;
receptor
1.48x10-15
Gdf10; Il15ra; Il11; Tslp; Tnfsf14; Ccl20; Gdf15; Tnfrsf9; Lif;
interaction
Gdf6; Ngf; Cxcl10; Bmp2; Il6; Il7; Tnfsf4; Tnfsf9; Fas; Tnfrsf25;
Inha; Il17a
Mmp1b; Csf3; Ccl12; Ccl20; Mmp3; Tnfaip3; Cxcl1; Cxcl3;
IL-17 signaling
2.38x10-13 Ptgs2; Cxcl2; Tnf; Mmp9; Cxcl5; Nfkbia; Fosl1; Mapk11;
pathway
Cxcl10; Il6; Mmp13; Ccl7; Traf5; Ccl2; S100a8; Il17a
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Ccl12; Oas1a; Tnfaip3; Cxcl1; Nod2; Cxcl3; Tnf; Cxcl2; Oas1g;
NOD-like
Ccl5; Nlrp3; Ccl2; Gbp2; Camp; Gbp3; Gsdmd; Gbp5; Gbp7;
receptor signaling 2.56x10-11
Ifi207; Ifi204; Ripk2; Cybb; Tmem173; Nfkbia; Mapk11; Il6;
pathway
Aim2; Oas2; Oas3; Traf5; Irf7; Txnip; Birc3
H2-t22; H2-q6; H2-k1; H2-q4; Oas1a; Tnfaip3; Pik3cd; Tnf;
Icam1; Oas1g; Relb; Bid; Entpd1; H2-eb1; Syk; Gadd45a;
Epstein-Barr virus
2.89x10-11 Ddx58; Isg15; H2-aa; Nfkb2; Tapbp; Nfkbia; Cxcl10; Mapk11;
infection
Il6; Oas2; Oas3; Traf5; Cyct; Irf7; Fas; Cd247; Nfkbie; Cd44;
Tlr2
Rheumatoid
arthritis

8.78x10-9

Mmp1b; Il11; Ccl12; H2-eb1; Csf1; Ccl20; Cd80; Mmp3; Tnf;
H2-aa; Cxcl5; Icam1; Vegfa; Il6; Ccl5; Ccl2; Tlr2; Il17a
24 hour

TNF signaling
pathway

Csf1; Tnfaip3; Cxcl1; Nod2; Cxcl3; Tnf; Cxcl2; Cx3cl1; Icam1;
Creb3l3; Ccl5; Ccl2; Edn1; Vcam1; Mlkl; Ccl20; Mmp3; Lif;
3.06x10-18
Ifi47; Traf1; Sele; Mmp9; Mapk13; Nfkbia; Cxcl10; Mapk11;
Irf1; Traf5; Fas; Birc3

Csf1r; Cxcl9; Csf1; Il23r; Il1f9; Cxcr4; Cxcl1; Cxcl13; Cxcl3;
Cytokine-cytokine
Il2rg; Tnf; Cxcl2; Cx3cl1; Il27ra; Cxcl16; Il1rl1; Il1rl2; Ccl9;
-13
receptor
1.89x10 Il18rap; Acvr1c; Ccl7; Ccl5; Ccl2; Il13ra2; Ccr3; Il15ra; Il33;
Tslp; Ccl20; Gdf15; Lif; Ngf; Bmp4; Cxcl10; Bmp3; Bmp2;
interaction
Tnfsf4; Lep; Tnfsf9; Fas; Il17a
Oas1a; Tnfaip3; Cxcl1; Nod2; Cxcl3; Tnf; Cxcl2; Ccl5; Nlrp3;
NOD-like
Ccl2; Gbp2; Camp; Gbp3; Gsdmd; Gbp5; Gbp7; Ifi207; Ifi204;
receptor signaling 4.99x10-12
Ripk2; Cybb; Tmem173; Mapk13; Nfkbia; Mapk11; Aim2; Oas2;
pathway
Oas3; Traf5; Irf7; Txnip; Nfkbib; Birc3
Mmp1b; Ccl20; Mmp3; Tnfaip3; Cxcl1; Cxcl3; Cxcl2; Tnf;
IL-17 signaling
-11 Mmp9; Mapk13; Nfkbia; Fosl1; Mapk11; Cxcl10; Mmp13; Ccl7;
9.66x10
pathway
Traf5; Ccl2; S100a8; Il17a
H2-t22; H2-q6; H2-k1; H2-q7; H2-q4; Oas1a; Tnfaip3; Tnf;
Epstein-Barr virus
Icam1; Relb; Bid; Syk; Gadd45a; Isg15; H2-aa; Nfkb2; Tapbp;
4.34x10-10
Mapk13; Nfkbia; Cxcl10; Mapk11; Oas2; Oas3; Traf5; Irf7; Fas;
infection
Cd247; Nfkbie; Cd44; Tlr2; Nfkbib
72 hour
TNF signaling
pathway

3.35x10-20 Cebpb; Ccl12; Csf1; Tnfaip3; Cxcl1; Nod2; Cxcl3; Tnf; Cxcl2;
Cx3cl1; Icam1; Casp7; Creb3l3; Ccl5; Ccl2; Ikbkg; Junb; Edn1;
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Vcam1; Mlkl; Ccl20; Mmp3; Lif; Ifi47; Traf1; Tnfrsf1b; Sele;
Mmp9; Mapk13; Nfkbia; Mapk10; Cxcl10; Mapk11; Il6; Irf1;
Fas; Creb5; Birc3
Cntfr; Cxcl9; Mstn; Csf1; Il23r; Il1f9; Cxcl1; Cxcl3; Tnf; Cxcl14;
Cxcl2; Cx3cl1; Cxcl15; Cxcl16; Bmp15; Il18rap; Il13ra2; Il11;
Cytokine-cytokine
Ifngr2; Il19; Il17re; Tnfrsf1b; Ngf; Prlr; Csf1r; Ccl12; Il20rb;
receptor
9.89x10-16 Cxcr4; Tnfrsf11a; Il2rg; Il1rl1; Il1rl2; Ccl9; Ccl8; Ccl7; Ccl5;
Ccl2; Il12rb1; Gdf10; Tslp; Tnfsf14; Tnfsf15; Ccl20; Gdf15; Il34;
interaction
Tnfrsf9; Lif; Bmp8a; Gdf5; Cxcl10; Bmp2; Il6; Tnfsf4; Lep;
Tnfsf9; Fas
Mmp1b; Cebpb; Ccl12; Tnfaip3; Cxcl1; Cxcl3; Cxcl2; Tnf; Ccl7;
IL-17 signaling
Ccl2; Ikbkg; Ikbke; Ccl20; Mmp3; Il17re; Mmp9; Mapk13;
4.44x10-12
Nfkbia; Mapk10; Fosl1; Mapk11; Cxcl10; Il6; Mmp13; Traf4;
pathway
S100a8
Ccl12; Prkaa2; Gstt4; Pdgfb; Mgst1; Calml3; Calml4; Tnf;
Fluid shear stress
Prkcz; Actg1; Icam1; Nppc; Hmox1; Ccl2; Ikbkg; Mef2c; Edn1;
and
1.04x10-10
Vcam1; Gstm1; Cav3; Gsto1; Sele; Mmp9; Ass1; Mapk13; Vegfa;
atherosclerosis
Mapk10; Mapk11; Gsta4; Gsta3; Gsta1
ECM-receptor
interaction

Pathways in
cancer

Lama2; Lamc3; Itga2; Tnc; Lamc2; Thbs2; Thbs4; Col1a1;
9.57x10-10 Col2a1; Reln; Col1a2; Ibsp; Sv2b; Col4a4; Chad; Itga11;
Col9a1; Itgb7; Col9a3; Col9a2; Cd44; Itga9
Mmp1b; Lamc3; Il23r; Calml3; Lamc2; Calml4; Gli1; Fgf7;
Casp7; Bdkrb1; Ikbkg; Edn1; Gsto1; Dapk2; Ifngr2; Itga2; Traf1;
Mmp9; Agtr1a; Traf4; Col4a4; Met; Birc3; Camk2b; Csf1r;
Notch3; Lama2; Ptger2; Gstt4; Pdgfb; Mgst1; Cxcr4; Adcy1;
1.38x10-9
Lpar4; Il2rg; Hmox1; Pmaip1; Gng8; Bid; Il12rb1; Egln1; Arnt2;
Wnt10a; Egln3; Fzd2; Gstm1; Gadd45b; Nos2; Fzd4; Gadd45a;
Txnrd1; Fzd6; Fzd8; Vegfc; Agt; Nfkb2; Vegfa; Nfkbia; Mapk10;
Bmp2; Il6; Gsta4; Gsta3; Gsta1; Mdm2; Fas; Fgfr3

Col18a1; Col15a1; Col27a1; Kcne3; Eln; Col11a1; Col22a1;
Protein digestion
Col11a2; Atp1a3; Atp1b1; Slc8a1; Col1a1; Col3a1; Col2a1;
5.02x10-9
Col1a2; Slc7a8; Col5a1; Col4a4; Col5a3; Col9a1; Col9a3;
and absorption
Col9a2
Csf1; Lamc3; Tnc; Lamc2; Areg; Fgf7; Creb3l3; Ibsp; Itgb7;
PI3K-Akt
1.26x10-8 Ikbkg; Syk; Itga2; Ngf; Prlr; Ereg; Col2a1; Col4a4; Ddit4; Met;
signaling pathway
Epha2; Tlr2; Creb5; Itga9; Csf1r; Prkaa2; Lama2; Pdgfb; Lpar4;
Il2rg; Thbs2; Thbs4; Pik3r5; Reln; Chad; Gng8; Pck1; Angpt4;
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Vegfc; Vegfa; Col1a1; Il6; Col1a2; Ppp2r2c; Itga11; Col9a1;
Mdm2; Col9a3; Col9a2; Fgfr3
Pertussis
Rheumatoid
arthritis

2.07x10-7

C1qb; C1qa; Nos2; Itgb2; Calml3; Calml4; Tnf; C2; Mapk13;
C3; Mapk10; Mapk11; Casp7; Il6; C1s1; Irf1; Nlrp3; C1qc

Mmp1b; Il11; Ccl12; Csf1; Ccl20; Cd80; H2-dma; Itgb2; Mmp3;
2.09x10-7 Tcirg1; Tnfrsf11a; Tnf; Icam1; Vegfa; H2-dmb2; Il6; Ccl5; Ccl2;
Tlr2
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Education
Washington University in St. Louis
Doctor of Philosophy Candidate in Biomedical Engineering
Expected Defense: April 16, 2020
Duke University
Master of Science in Biomedical Engineering

January 2016 - present

August 2014 - December 2015

University of Missouri – Columbia
Bachelor of Science in Bioengineering

August 2010 – May 2014

Research Experience
PhD Candidate in Biomedical Engineering at Washington University in St. Louis
2016 – Present
Research Advisor: Dr. Farshid Guilak, PhD
Department of Orthopaedic Surgery, Center of Regenerative Medicine, and Musculoskeletal
Research Center
•
•

Investigating the role of microRNAs in the inflammatory response of cartilage through the
integration of RNA and small RNA sequencing data to understand the mechanisms driving
osteoarthritis
Characterized a self-regulating synthetic transcription system for the attenuation of inflammatory
signaling in tissue engineered cartilage

Master’s student in Biomedical Engineering at Duke University
2014-2016
Research Advisor: Dr. Farshid Guilak
Orthopaedic Research Laboratory
•
•

Researched the chondrogenic potential of lentivirally transduced, adipose derived stem cells in an
inflammatory environment for cartilage tissue engineering
Conducted biochemical and histological analysis to determine matrix production and tissue
deposition on a polymer scaffold, as well as transgene production

Research Experience for Undergraduates and Honors Research
Summer 2013 – Spring 2014
Research Advisors: Dr. Shubhra Gangopadhyay and Dr. Sheila Grant
National Science Foundation/University of Missouri – Columbia
Bioengineering and Electrical & Computer Engineering Departments
•

Studied and researched plasmonics and photonics to create an inexpensive and easily
reproducible biosensing platform
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Undergraduate Researcher
Summer 2012
Research Advisor: Dr. Sheila Grant
Bioengineering Department, University of Missouri – Columbia
•

Synthesized a novel biological scaffold with increased thermal stability and cellularity by
conjugating porcine collagen fibrils with gold nanoparticles

Other Experiences
Biotechnology Equity Research Fellow
September 2019 – February 2020
Kennedy Capital Management, Inc.
St. Louis, MO
• Provide fundamental research on biotechnology and pharmaceutical industries to
healthcare analysts and portfolio managers
• Analyze company pipelines, financials, and catalysts, attend conferences, and interview
and join calls with key opinion leaders and management teams
Consultant - The BALSA Group
Fall 2019
St. Louis, MO
• Conducted market research and competitor analysis for a novel imaging technology
throughout a 6-week project
• Presented summarized findings and guidance to the Office of Technology Management at
Washington University in St. Louis

Honors and Awards
2018-2019
2018
2014-2017
2014
2010-2014

Philip and Sima Needleman Student Fellowship in Regenerative Medicine
Bioinformatics Research Core Microgrant Program – Center of Regenerative
Medicine, Washington University in St. Louis
National Science Foundation – Graduate Research Fellowship Program
Fellow
Outstanding Biological Engineering Senior, University of Missouri –
Columbia
Academic Excellence Award, University of Missouri – Columbia

Publications
Ross AK, Coutinho de Almeida R, Ramos YFM, Li J, Meulenbelt I, & Guilak F. (2020). The
miRNA-mRNA Interactome of murine iPSC-derived Chondrocytes in Response to
Inflammatory Cytokines. Manuscript submitted for publication.
Guilak F, Pferdehirt L, Ross AK, Choi, YR, Collins K, Nims RJ, Katz DB, Klimak M,
Tabbaa S, & Pham CT. (2019). Designer Stem Cells: Genome Engineering and the Next
Generation of Cell‐Based Therapies. Journal of Orthopaedic Research®, 37(6), 1287-1293.
122

Pferdehirt L*, Ross AK*, Brunger JM, & Guilak F (2019). A synthetic gene circuit for selfregulating delivery of biologic drugs in engineered tissues. Tissue Engineering Part A, 25(910), 809-820.
Moutos FT, Glass KA, Compton SA, Ross AK, Gersbach CA, Guilak F, and Estes BT.
(2016) Anatomically shaped tissue-engineered cartilage with tunable and inducible
anticytokine delivery for biological joint resurfacing. Proceedings of the National Academy
of Sciences, 113(31), E4513-E4522.

Posters and Presentations
Ross AK, Coutinho de Almeida R, Ramos YFM, Li J, Meulenbelt I, & Guilak F. Modulating
the miRNA Interactome of iPSC-derived Chondrocytes to Control the Response to
Inflammatory Stimuli. Orthopaedic Research Society 66th Annual Meeting; 2020 Feb 7-11;
Phoenix, AZ. Poster presentation by Ross AK.
Ross AK, Pferdehirt LG, Guilak F. MicroRNA-sequencing Reveals Specific Mediators of
Inflammation in Tissue Engineered Cartilage. Orthopaedic Research Society 65th Annual
Meeting; 2019 Feb 2-5; Austin, TX. Poster presentation by Ross AK.
Pferdehirt LG, Ross AK, Brunger JM, Guilak F. A Synthetic Transcription System Based on
NF-kB Signaling for Cartilage Tissue Engineering Using Self Regulating Delivery of
Therapeutic Biologic Drugs. Orthopaedic Research Society 64th Annual Meeting; 2018 Mar
9-13; New Orleans, LA. Podium presentation by Ross AK.
Moutos FT, Glass KA, Compton SA, Ross AK, Gersbach CA, Guilak F, Estes BT.
Anatomically-Shaped Tissue Engineered Cartilage with Tunable and Inducible AntiCytokine Delivery for Biological Joint Resurfacing. Orthopaedic Research Society 62nd
Annual Meeting; 2016 Mar 5-8. Orlando, FL. Podium presentation by Moutos FT,
Glass KA, Ross AK, Compton SA, Gersbach CA, Moutos FT, Estes BT, Guilak F.
Anatomically-Shaped Tissue-Engineered Cartilage with Tunable and Inducible AntiInflammatory Capabilities. Tissue Engineering and Regenerative Medicine International
Society, Inc. (TERMIS)-AM World Congress 4th Annual meeting; 2015 Sept 8-11; Boston,
MA. Podium presentation by Glass KA.
Guilak F, Brunger JM, Zutshi A, Willard VP, Glass KA, Ross AK, Moutos FT, Estes BT,
and Gersbach CA. Targeted Genome Engineering to Program Artificial Intelligence into
Stem Cells for Regenerative Medicine. Regenerative Medicine Workshop at Hilton Head
(Keynote presentation by Guilak F); 2015 May 13-16; Hilton Head Island, SC.
Spradling C, Ross A, Grant D, Grant D, Grant S. Development of a Novel Gold
Nanoparticle-Collagen Scaffold for Soft Tissue Applications. Biomedical Engineering
Society 44th Annual Meeting; 2012 Oct 24-27; Atlanta, GA. Poster presentation by Spradling
C and Ross AK.
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Teaching and Mentoring Experience
Mentor to Washington University Biomedical Engineering student researchers
2016 - present
• Mentored an undergraduate part-time, a masters student, and a PhD student
• Trained students in laboratory techniques for orthopaedic tissue engineering, molecular
biology, gene therapy, experiment design, and data collection and analysis
Teaching Assistant – Biomedical Engineering Design (BME 401)
2017-2018
• Mentored student groups in device design, validation, and presentation to industry
representatives for a variety of biomedical engineering problems
• Gave a lecture on engineering design principles

Leadership Experience
Biomedical Engineering Doctoral Student Council
Washington University in St. Louis
Cohort Representative, 2017-2018
Chair, May 2018 – May 2019
• Advocated for the interests of the graduate students to the Department of Biomedical
Engineering
• Organized inter-disciplinary academic and professional development activities,
departmental social activities, and prospective student recruitment
Biomedical Engineering Association of Master’s Students
Duke University
President, May 2015 – December 2015
• Presented at seminar sessions for incoming MS students on academic, professional, and
social topics
• Acted as a liaison between the Biomedical Engineering Department and MS students

Community Service
Young Scientist Program
Continuing Mentor for High Schoolers
2016 – 2019
• Mentor high school students from disadvantaged backgrounds into scientific careers and
provide resources for their academic success
• Provided career and collage guidance, lead students in a science project, and assisted with
standardized test preparation
The Perry Initiative
Perry Outreach Program
• Assisted high school age women with mock orthopaedic surgery and biomechanical
engineering activities
Acted as a mentor to young females interested in medical and engineering fields
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